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POPULÄRVETENSKAPLIG SAMMANFATTNING
 
Njurarna har flera livsviktiga funktioner. Från blodet till urinen filtrerar njurarna bort 
nedbrytnings- och restprodukter, gifter och läkemedel. De reglerar vätske-, salt-, och syra-
bas-balansen i blodet och producerar även aktiva hormoner som är involverade i 
nybildningen av röda blodkroppar, kalcium-omsättningen, och regleringen av blodtrycket (1). 
Njurarna är två bönformade organ som vilar i bukens bakre del bakom bukhinnan, på var sin 
sida om kotpelaren. De omges av var sin kapsel med en öppning vid mitten av njuren där 
nerver, lymfkärl, njurartär, njurven, och urinledare ansluter. Trots sin ringa storlek, är 
njurarna normalt väl genomblödda och de erhåller cirka 20% av det totala blodflödet från 
hjärtat. Dock bjuder kärlen i njurarna på ett gott flödesmotstånd vilket bygger upp ett tryck i 
de kärl som skall filtrera blod till urin. I vardera njure finns cirka 1 miljon urinproducerande 
enheter som kallas nefron. Nefronet börjar med ett läckande mikroskopiskt blodkärlnystan 
med specifik filterstorlek och negativ laddning och släpper igenom små och företrädelsevis 
positivt laddade molekyler. Detta kärlnystan är omgivet av en kapsel där primärurin samlas 
upp och strömmar till ett anslutande rör (tubuli) som är nästa del av nefronet. Primärurinen 
passerar genom tubuli och koncentreras genom att vatten och många molekyler 
återabsorberas ut till blodet. Utan återresorptionen från primärurinen skulle motsvarande hela 
blodvolymen utsöndras på cirka 30 minuter. En molekyl som knappt återresorberas alls är 
nedbrytningsprodukten kreatinin. Kreatininets koncentration i blodet speglar därför njurens 
filtrationsförmåga väl, utan att störas av variation i återresorptionen. Den lämpar sig därmed 
väl som en markör för njurens filtrationsförmåga, framförallt på kort sikt (1). 
Akut njurskada, tidigare kallat akut njursvikt, är en plötslig försämring av njurfunktionen. 
Diagnosen akut njurskada ställs genom att mäta koncentrationen av kreatinin i blodet 
alternativt genom att mäta urinproduktionen. En ökning av kreatinin-koncentrationen på >26 
µmol/L inom två dygn eller en urinproduktion som sjunker till <0,5 ml/kg kroppsvikt/timme 
under ≥6 timmar definieras som akut njurskada. I vissa fall kan orsaken till akut njurskada 
ställas genom vidare provtagning men i många fall saknas specifika diagnostiska test. Istället 
fastställs orsaken genom en sammanvägd klinisk bedömning. Möjliga skademekanismer är 
många och akut njurskada beskriver endast att en skada har skett men säger inget om orsaken. 
Akut njurskada drabbar ofta patienter som är kritiskt sjuka, exempelvis vid blodförgiftning 
samt vid stor kirurgi. Särskilt vanligt är akut njurskada vid hjärtkirurgi. Riskfaktorer för akut 
njurskada är bland annat hög ålder, hjärtsvikt, kronisk njursjukdom och diabetes. Orsakerna 
kan vara syrebrist till följd av lågt blodtryck, inflammation, och förekomst av molekyler eller 
gifter som skadar nefronerna. Vid svår akut njurskada kan filtrationsförmågan påverkas till 
den grad att dialys är nödvändig. Under det senaste decenniet har dock allt mer 
uppmärksamhet riktats åt mildare akuta njurskador och dess betydelse. Vid mildare akut 
njurskada normaliseras ofta kreatinin-koncentrationen och urinproduktionen inom några 
dagar från att skadan har inträffat. Traditionellt sett har man därmed menat att njurarna är bra 
på att återhämta sig. Flertalet nya studier har dock visat att det finns ett samband mellan 
mildare grader av akut njurskada och ökad sjukdomsbörda och försämrad prognos på längre 
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sikt även om njurfunktionen återhämtar sig. Frågan är om akut njurskada i sig skadar kroppen 
och leder till sjukdom eller om akut njurskada är ett sekundärt tecken på sjukdom och ökad 
sårbarhet i andra organ än i njuren, som till exempel i hjärtat. Forskare inom området är 
väsentligen överens om att akut njurskada orsakar sjukdom och skada, vilket har negativa 
konsekvenser även om kreatininkoncentrationen och njurfiltrationen normaliseras efter 
skadan. 
I denna avhandling studeras patienter som genomgår hjärtkirurgi där akut njurskada är vanligt 
förekommande. Akut njurskada drabbar mellan 5 till 30% av patienterna beroende på typ av 
kirurgisk intervention och definition på akut njurskada. Studierna berör njurskadlig 
läkemedelsbehandling, riskfaktorer för akut njurskada och vilka konsekvenserna för de som 
drabbas av akut njurskada kan bli.  
I första studien undersökte vi om patienter som fick ett tillägg av antibiotikan teicoplanin till 
ordinarie förebyggande antibiotikabehandling i samband med hjärtkirurgi hade en ökad risk 
för akut njurskada. Resultaten visade att patienter som behandlats med teicoplanin hade en 
40% ökad risk att utveckla akut njurskada jämfört med de som inte fick teicoplanin.  
I den andra studien undersökte vi om det fanns ett samband mellan typ 1 eller typ 2 diabetes 
och en ökad risk för att utveckla akut njurskada i samband med kranskärlskirurgi (ibland 
kallad bypass eller kranskärl-bypass). Resultaten visade att typ 1 diabetes var förenat med en 
nästan femdubbelt ökad risk för att utveckla akut njurskada, och typ 2 diabetes var förenat 
med 25% ökad risk. 
I den tredje studien undersökte vi om patienter som drabbats av akut njurskada efter 
kranskärlskirurgi hade en ökad risk att utveckla hjärtsvikt på lång sikt. Med en 
uppföljningstid på cirka 4 år i snitt kunde vi visa på att patienter som drabbades av akut 
njurskada hade nästan fördubblad risk att drabbas av hjärtsvikt. 
I den fjärde studien undersökte vi om minimala förändringar i njurfunktionen efter 
kranskärlskirurgi var förenade med ökad risk för död på kort och lång sikt. Vi undersökte 
även om man löpte större risk att dö, eller drabbas av antingen hjärtsvikt, hjärtinfarkt, eller 
stroke som ett kombinerat utfall. Resultaten visade att även minimala förändringar i 
njurfunktionen var förenade med ökad dödlighet på lång sikt, men ej på kort sikt, samt en 
ökad risk för det kombinerade utfallet död, hjärtsvikt, hjärtinfarkt eller stroke. 
Sammanfattningsvis har avhandlingens studier bidragit med en ökad förståelse kring 
riskfaktorer och konsekvenser av akut njurskada i samband med hjärtkirurgi. Resultaten kan i 
framtiden användas för att förbättra hälsovinsten av hjärtkirurgi ytterligare. 
På framsidan ses en retuscherad version av illustrationen av den Vitruvianske mannen 
tecknad av Leonardo da Vinci. Bilden är ett exempel på hur konst och vetenskap förenades 
under Renässansen. Njurar är tillagda och på bröstet finns ett snitt som illustrerar ärret efter 
en hjärtoperation. Den blottande positionen liknar i ett liggande läge patientens utsatta 
position på operationsbordet.   
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ABSTRACT 
 
Background: Acute kidney injury (AKI) is defined as a sudden decrease in renal filtration 
function. It is common among critically ill patients and patients undergoing major surgery, 
especially cardiac surgery. AKI is defined by either an elevated serum creatinine (SCr) 
concentration or a decrease in urine production. Because AKI often presents secondary to 
many other critical diseases and conditions, it has historically received little attention. During 
the last decade, however, AKI has received greater attention, and even minor AKIs has been 
clinically recognized. Recent studies have shown that patients who develop AKI have a 
worse prognosis. The aim of this thesis was to further investigate the risk factors for and 
outcomes of AKI in patients undergoing cardiac surgery. 
Patients and methods: Patients undergoing cardiac surgery were studied. The cohorts were 
identified using the SWEDEHEART register. The first study was performed to investigate 
whether prophylactic use of the antibiotic teicoplanin is associated with an increased risk of 
AKI (n = 2809 patients). The second study was performed to investigate whether type 1 
diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) are risk factors for the 
development of AKI after coronary artery bypass grafting (CABG) (n = 36,106 patients). The 
third study was carried out to determine whether patients who developed AKI after CABG 
had an increased long-term risk for developing heart failure (n = 24,018 patients). Finally, the 
fourth study was performed to investigate whether even minimal increases in the SCr 
concentration after CABG are associated with long- and short-term mortality and the 
composite outcome of long-term mortality, heart failure, myocardial infarction, and stroke (n 
= 25,686 patients).  
Results: Antibiotic prophylaxis with teicoplanin was associated with an increased risk of 
AKI after cardiac surgery. Additionally, a dose-dependent relationship was identified where a 
600-mg dose had a higher odds ratio (OR) than a 400-mg dose of teicoplanin. Both patients 
with T1DM and T2DM had a significantly higher risk of developing AKI after CABG than 
patients without diabetes; patients with T1DM had a higher risk than those with T2DM. 
Patients who developed AKI after CABG had an increased long-term risk of developing heart 
failure. AKI was also associated with increased long- and short-term mortality and an 
increased risk of the combined outcome of long-term mortality, heart failure, myocardial 
infarction, or stroke. Even minimal increases in the SCr concentration of 0 to 26 µmol/L was 
associated with increased long-term mortality, and the combined outcome, but was not 
associated with short-term mortality. 
Conclusion: Patients treated with teicoplanin and patients with T1DM or T2DM are at an 
increased risk of developing AKI in cardiac surgery. Patients developing AKI after CABG 
have an increased long-term risk of developing heart failure. Minimal increases in serum 
creatinine is associated with an increased long-term risk of death and cardiovascular events. 
AKI but not minimal increases in SCr was associated with increased 30-day mortality. 
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INTRODUCTION 
 
Acute kidney injury (AKI) is defined as a sudden decrease in glomerular filtration rate (GFR) 
that results in decreased urine production and increased blood concentrations of solutes 
normally filtered from blood to urine. The definition of AKI covers the whole spectrum of 
renal dysfunction from a minor decline in GFR to renal failure requiring dialysis. Studies 
have shown that AKI is associated with higher mortality, a longer hospital stay, and the 
development of chronic kidney disease (CKD) in a variety of settings (2–4). Historically, 
most research has focused on severe reductions in GFR, in some instances requiring dialysis. 
Minor kidney injuries have received less attention. One explanation for this is the kidneys’ 
high capacity to clinically recover their GFR; it has been thought that the kidneys readily heal 
after an insult. However, studies have suggested that even a transient decline in renal function 
is associated with an increased risk of developing CKD (5,6). 
Cardiac surgery includes cardiac revascularization, valve surgery, and surgery involving the 
chamber walls and large adjacent blood vessels. AKI is a frequent complication after cardiac 
surgery, with an incidence of approximately 10% to 30% depending on the type of cardiac 
procedure performed (4,7). Etiological risk factors for AKI specific to cardiac surgery are 
factors mostly related to the use of cardiopulmonary bypass (7). Risk factors for AKI in both 
cardiac surgery and non-cardiac surgery include blood transfusion, hypotension, systemic 
inflammation, anemia, and the use of certain drugs such as antibiotics (8). Based on results 
from earlier studies, the development of AKI after cardiac surgery is important and needs 
further exploration. It will also be helpful to study AKI as a phenomenon in the cardiac 
surgery setting, not only because AKI is common but also because cardiac procedures are 
well standardized in many cases and the patients form a quite homogenous group. This is in 
contrast to for example the intensive care setting, in which AKI is common but the reasons 
for admission are much more heterogeneous. 
The aim of this thesis was to further investigate the risk factors for and outcomes of AKI in 
patients undergoing cardiac surgery. 
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BACKGROUND 
 
HISTORICAL PERSPECTIVE OF ACUTE KIDNEY INJURY 
Acute renal failure has long been known as a devastating disorder. During World War I, 
many wounded soldiers developed “war nephritis” after traumatic injuries likely associated 
with rhabdomyolysis, shock, and sepsis (3). One of the earliest reports of acute renal failure 
in the 20th century was on war nephritis, published in The Lancet 1917 (9). Later, during 
World War II in 1941, a male leather worker became trapped beneath the debris of a 
demolished hostel and was hospitalized for a severe crush injury on his left leg. However, his 
urine production stopped and he died 6 days later. Autopsy showed swollen kidneys, and 
histological specimens showed tubular pigment casts. This case was described by Beall et al. 
and is one of the earliest published articles on acute renal failure with a pathophysiologic 
description (10). In 1945, Dr. Willem Kolff described the first survivor of dialysis. Later, in 
1947, Bywaters began using hemodialysis to treat renal failure. In 1951, the term “acute renal 
failure” was introduced in the chapter entitled “Acute renal failure related to traumatic 
injuries” in the textbook The Kidney: Structure and Function in Health and Disease. In 1967, 
Silverstein developed hemofiltration, which increased the range of AKI treatments, and in 
1979, Kramer developed continuous arteriovenous hemofiltration (3). 
 
DEFINITION OF ACUTE KIDNEY INJURY 
In 1994, a meta-analysis on risk factors for acute renal failure after surgery was published. 
The analysis included 28 studies, but none of them used the same definition of acute renal 
failure (11). This study highlighted the lack of uniform diagnostic criteria for acute renal 
failure, which made comparisons among studies very difficult (12). In an attempt to unify the 
diagnostic criteria for acute renal failure, the Acute Dialysis Quality Initiative published a 
consensus definition of acute renal failure called the Risk, Injury, Failure, Loss of kidney 
function, and End-stage renal disease (RIFLE) criteria in 2004 (13). Acute renal failure was 
also renamed AKI. Traditionally, the term “acute renal failure” was closely associated with 
the need for dialysis; therefore, the new term “acute kidney injury” was established to 
emphasize that even minor changes in renal function require further attention. The AKI era 
was thus started. The RIFLE criteria classify AKI according to a relative increase in the SCr 
concentration, or decrease in GFR, or a decrease in urine output. Five stages of severity were 
defined (Table 1). Since the RIFLE criteria were introduced, there was an increased interest 
in the clinical effects of AKI. The RIFLE criteria have been evaluated in different clinical 
settings, including critical care and cardiac surgery (14–17). Studies using the RIFLE criteria 
have shown a stepwise association with the stage of AKI and worse clinical outcomes such as 
increased mortality, longer intensive care unit stay, and reduced renal recovery (14–17). Even 
a transient decrease in renal function is associated with increased mortality (18).  
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Since the RIFLE criteria was introduced further effort has been put to find an optimal 
definition of AKI that could both serve as a sensitive and specific definition and also be easy 
to use in both research and clinical practice. In 2007, the Acute Kidney Injury Network 
(AKIN) revised the RIFLE criteria by adding an absolute change in the SCr concentration of 
26 µmol/L within 48 hours to AKI stage 1 and excluding the GFR criteria (19). The 
additional criterion of an absolute change in the SCr concentration increased the sensitivity 
for AKI stage 1 (20). Renal replacement therapy was excluded from the AKIN criteria 
because this therapy was regarded as an outcome of AKI rather than an AKI stage (19). The 
RIFLE and AKIN criteria were later unified with the 2012 Kidney Disease: Improving 
Global Outcomes (KDIGO) criteria (Table 1) (21). The KDIGO criteria include both a short 
(24-hour) and extended (48-hour) time frame for the diagnosis of AKI. KDIGO also 
reintroduced a GFR criterion for stage 3 AKI, but the criterion was limited to patients <18 
years of age. 
Since 2004, many studies have used the RIFLE, AKIN, and KDIGO consensus criteria. 
However, a lot of them have not included urine output criteria because such data are often 
unavailable in observational cohort studies. Therefore, evidence for changes in urine output is 
relatively weak (17). Additionally, the widespread use of diuretics in belief to improve the 
outcome in AKI or to improve the patient’s fluid balance, further complicates the use of urine 
output criteria. It has been argued that the KDIGO stage 1 criterion of a urine output of <0.5 
mL/kg/h for 6 hours is too liberal and not as closely associated with mortality and dialysis as 
is the SCr criterion for AKI stage 1 (22). A cutoff value of 0.3 instead of 0.5 mL/kg/h has 
been found to be a better predictor (22). 
A weakness of the SCr criteria is that AKI and an elevated SCr concentration might already 
be present when the patient is admitted to the hospital (23). A further increase in the SCr 
concentration after admission might underestimate the true severity of AKI. There have 
earlier been attempts to back-calculate the baseline SCr concentration from algorithms 
originally aimed at estimating the GFR. These algorithms often include age, sex, and weight. 
However, these calculations have been shown to be imprecise and to have a low specificity 
for the diagnosis of AKI than using the true baseline SCr concentration (24). Several 
investigators are currently focusing on serial measurements of the SCr concentration within a 
short time period and estimation of AKI according to SCr kinetics and variability (25).  
  
 16 
Table 1. Definition of AKI according to the RIFLE (13), AKIN (19) and KDIGO (21) criteria. 
AKI stage Increase in serum creatinine concentration  Urinary output criteria 
RIFLE   
Risk ≥1.5- to 2-fold increase, or decrease in GFR >25%  <0.5 ml/kg/h for ≥6h to <12 hours 
Injury ≥2.0- to 3.0-fold increase, or decrease in GFR 
>50% 
<0.5 ml/kg/h for ≥12h 
Failure ≥3.0-fold, or 44 µmol/l absolute increase if 
baseline SCr ≥354 µmol/l or decrease in GFR 
≥75% 
<0.3 ml/kg/h for ≥24h or anuria for 
≥12 h 
Loss of Kidney 
Function 
Complete loss of renal function for >4 weeks  
End-stage Renal 
Disease 
End-stage renal disease >3 months  
AKIN   
Stage 1 ≥1.5- to 2-fold increase, or ≥26.4 µmol/l absolute 
increase within 48 h 
<0.5 ml/kg/h for >6h to 12 hours 
Stage 2 >2.0- to 3.0-fold increase <0.5 ml/kg/h for >12h 
Stage 3 >3.0-fold increase, or ≥44 µmol/l absolute if 
baseline ≥354 µmol/l 
<0.3 ml/kg/h for ≥24h or anuria for 
≥12 h 
KDIGO   
Stage 1 ≥1.5- to 1.9-fold increase within 7 days, or >26.5 
µmol/l within 48 hours 
<0.5 ml/kg/h for 6 to 12 h 
Stage 2 ≥2.0- to 2.9-fold increase within 7 days <0.5 ml/kg/h for ≥12 hours 
Stage 3 ≥3.0-fold increase, or >354 µmol/l increase within 
7 days, or initiation of renal replacement therapy, 
or a decrease of GFR to <35 ml/min/1.73m2 in 
patients <18 years of age 
<0.3 ml/kg/h for ≥24h or anuria for 
≥12 h 
AKI = acute kidney injury, AKIN = Acute Kidney Injury Network, KDIGO = Kidney Disease: Improving 
Global Outcomes, RIFLE = Risk, Injury, Failure, Loss of kidney function, and End-stage renal disease. 
 
 
CHRONIC KIDNEY DISEASE AND ACUTE KIDNEY DISEASE  
Chronic kidney disease 
Aiming to devise a uniform nomenclature and definition of chronic renal dysfunction, the 
National Kidney Foundation Kidney Disease Outcomes Quality Initiative established a 
consensus classification of renal dysfunction in 2002 using the term “chronic kidney disease” 
(26). The definition of CKD has been refined and updated by the KDIGO CKD Work Group, 
which defines CKD as “abnormalities of kidney structure or function, present for >3 months, 
with implications for health” (27). The KDIGO criterion for CKD is either a GFR of <60 
mL/min/1.73 m2 for >3 months or signs of kidney damage for >3 months. Kidney damage is 
defined as the presence of one or more of the following: albuminuria, urine sediment 
abnormalities, electrolyte and other abnormalities due to tubular disorders, abnormalities 
detected by histology, structural abnormalities detected by imaging, or a history of kidney 
transplantation (27). CKD is staged according to cause of CKD, GFR category, and degree of 
albuminuria (Table 2) (27). The prognosis of CKD has been well studied and there has been 
found a strong association between CKD stages and increased risk of cardiovascular disease, 
and death (28). Both CKD and cardiovascular disease share several risk factors such as 
diabetes mellitus and obesity (29).  
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Table 2. Staging of chronic kidney disease according to KDIGO (27) 
GFR category Description of function GFR (mL/min/1.73m2) 
G1 Normal ≥90 
G2 Mildly decreased 60-89 
G3a Mildly to moderately decreased 45-59 
G3b Moderately to severely decreased 30-44 
G4 Severely decreased 15-29 
G5 Kidney failure <15 
Albuminuria category  Description of albuminuria Albumin (mg)/creatinine (mmol) 
A1 Normal <3 
A2 Moderately increased 3-30 
A3 Severely increased >30 
GFR = Glomerular filtration rate, KDIGO = Kidney Disease: Improving Global Outcomes. 
 
Acute kidney disease 
To further develop a uniform nomenclature of acute, subacute, and chronic renal dysfunction, 
the KDIGO AKI Work Group proposed the concept of “acute kidney disease” (30). The 
concept of acute kidney disease emphasizes the potentially vulnerable period after AKI 
during which some patients recover their renal function better than others. Further awareness, 
research, and focus of the period following AKI might enhance renal recovery and prevent 
patients from progressing to CKD. Acute kidney disease is defined as having or developing 
one or more of the following within the past 3 months: AKI, a GFR of <60 mL/min/1.73 m2, 
a ≥35% decrease in the GFR, a ≥50% increase in the SCr concentration, or signs of kidney 
damage.  
 
RENAL PHYSIOLOGY 
The kidneys perform three vital functions; excretion of waste products, homeostasis, and 
hormone production. They filter water-soluble metabolites, toxins, and drugs from blood to 
be excreted in the urine. They control the fluid-, salt- and acid-base balance in the blood. 
The kidneys also produce hormones involved in erythropoiesis, calcium-turnover, and 
regulation of fluid balance and blood pressure (1).  
Even though the weight of the kidneys is only 0.5% of total body weight, nearly 20% of 
cardiac output goes to the kidneys. The blood enters the kidneys via renal arteries that 
divide into progressively smaller branches until they become afferent arterioles located 
proximally to the glomerulus (Figure 1). After the glomerulus blood drains to efferent 
arterioles. The glomerulus is the first part of the nephron - an independent urine-producing 
unit of which there are roughly two million in the kidneys - and constitutes a cluster of 
blood vessels. The glomerulus has a greater permeability than other capillaries and filters 
molecules depending on their size and charge. The glomerular filtration barrier between the 
capillary lumen and bowman’s capsule is comprised of several layers with different filter 
sizes. One such layer is also negatively charged and is thought to prevent negative proteins 
from passing through. The filtered primary urine is collected in bowman’s capsule and 
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drained into the tubule. Approximately 180 L of primary urine is filtered daily through the 
glomerulus, however the majority is reabsorbed by the renal tubules leading to a urine 
output of approximately 1 ml/kg bodyweight/hr. The filtration over the glomerulus is a 
passive process driven by the blood pressure that is higher than both the hydrostatic 
pressure within bowman’s capsule, and the oncotic pressure exerted by the blood. The 
primary urine resembles plasma except that it contains very small amounts of proteins and 
thus has almost no oncotic pressure. 
The afferent arteriole and efferent arteriole regulates the blood pressure in the glomerulus 
and their tone is regulated by sympathetic innervation and chemical mediators (1). The 
efferent arteriole divides into peritubular capillaries that surround the tubule. The nephrons 
located in the juxtamedullary region form the vasa recta that pass down to the renal 
medulla. To maintain an adequate blood filtration capacity, the glomeruli need a high renal 
blood flow. The opposite is needed in the renal medulla where a low blood flow is 
necessary to maintain a high osmotic gradient. This enables fluid reabsorption from the part 
of the renal tubule that descends to the medulla to concentrate the primary urine. The renal 
blood flow is thereby unevenly distributed and only a minor portion is going to the renal 
medulla (1). The sodium resorption is energy consuming and is thought to be a large part of 
the renal oxygen consumption (31). Due to the relative low blood flow, but also a high 
metabolic activity, the renal medulla is exquisitely sensitive to decreased oxygen delivery. 
The renal autoregulation consists of two mechanisms that maintain renal blood flow and 
glomerular filtration; The first is a baroreceptor-mechanism in afferent arterioles. If the 
blood pressure drops it will lead to a decrease in wall tension/diameter in the arteriole. This 
will lead to a subsequent stimulation of neighboring granular cells to release renin into the 
circulation. Activating the renin-angiotensin-aldosterone-system lead to water retention and 
increased mean arterial pressure (32). The second mechanism is the tubuloglomerular 
feedback where the macula densa in the tubule reacts to decreased volume and sodium 
chloride concentration, signaling the afferent arteriole to dilate. The renal autoregulation 
has been studied in dogs and has been found to maintain renal blood flow down to a mean 
arterial pressure of 65 mmHg. However, after sympathetic stimulation this threshold 
increases to around 95 mmHg (33). 
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ACUTE KIDNEY INJURY BIOMARKERS 
Serum creatinine  
Creatinine is generated from breakdown of creatine. Creatine is a protein based on the amino 
acids glycine and arginine. The last step in the biosynthesis of endogenous creatine mainly 
occurs in the liver, but the precursor guanidinoacetate is mainly synthesized in the kidneys. 
Creatine is also ingested through the diet, mainly from meat, but is also a common 
supplement in sports nutrition to enhance athletic performance. It is transported to many 
organs via the blood and serves as a high-energy phosphate transporter for adenosine 
triphosphate production (34). The highest concentrations of creatine are found in skeletal 
muscle. In skeletal muscle, creatine acts as an adenosine triphosphate buffer and constitutes 
>90% of the body’s total pool of creatine and phosphorylcreatine (34). Creatine and 
phosphorylcreatine are spontaneously and irreversibly broken down to creatinine at an almost 
constant rate (34). A 70-kg man contains around 120 g of creatine and phosphorylcreatine, 
and around 1.7% (2 g) is converted to creatinine per day (34). Raw meat contains around 4 
g/kg of creatine. Creatinine is membrane-permeable and diffuses freely into the blood. It is 
freely excreted into the urine by glomerular filtration, and around 15% is also actively 
secreted into the urine by tubular cells (35). A minor proportion is metabolized or excreted in 
the feces (34). 
Figure 1.  
Illustration of renal anatomy and blood flow. Two 
nephrons are illustrated in the zoomed in inset. 
 20 
Because creatinine is produced at a constant rate, is almost metabolically inert, and is almost 
solely excreted by glomerular filtration, it can serve as a marker for the GFR. Urine stasis or 
an injury occurring between the glomerulus and collecting duct will inhibit excretion of 
creatinine via the urine, leading to a subsequent increase in the SCr concentration. An acute 
increase in the SCr concentration can be caused by AKI, but may also be caused by dietary 
intake, rhabdomyolysis, muscle trauma, and reduced tubular secretion secondary to certain 
medications such as trimethoprim and cephalosporins (36). Chronic causes of an increased 
SCr concentration are CKD, large muscle mass, and high intake of creatine (sports nutrition) 
(36). Among individuals with stable renal function, the SCr concentration varies by about 8% 
during the day (35).  
The SCr concentration has been criticized for being a late and unspecific marker for AKI 
(24). After a sudden decline in GFR it can take 24 to 48 hours before the SCr concentration is 
reaching a new steady state (37). Additionally, almost half of the nephrons can be lost 
without a change in the steady-state SCr concentration because of compensatory 
hyperfiltration (38). However, the author argues that the SCr concentration is not a poor 
marker in general; in fact, it is an adequate biomarker of GFR (38). The SCr concentration is 
a global marker for glomerular filtration, and an increase in the SCr concentration reveals 
effects of AKI from the glomerulus to the collecting duct. Few factors other than a change in 
GFR will cause a significant and acute change in the SCr concentration. The usefulness of the 
SCr concentration depends on the purpose for its use, in what setting it is being used, and 
how often it is measured. For example, is it being used for early detection in interventional 
studies? Or is it being used to study prognosis and risk factors? 
New biomarkers 
An ideal AKI biomarker would allow for instantaneous diagnosis of AKI, identification of 
the injury location and etiology, and prediction of the patient’s outcome. During the past 
decade, many new biomarkers for AKI have been identified, providing hope for further 
improvements in AKI diagnostics (39). These molecules are analyzed in blood or urine and 
serve as markers for estimated renal filtration function, structural injury or indirect signs of 
structural injury, and even cellular stress. The biomarkers are of various quality. Many are 
still undergoing validation, and very few have been introduced in clinical practice. There are 
still uncertainties regarding their cut-off values, sex- and age-related differences, and 
interpretation in different settings such as sepsis, cardiac surgery, and CKD (40,41). 
Currently, one of the most popular tests for AKI is the NephroCheck Test (Astute Medical 
Inc., San Diego, CA), which is the first point-of-care device to detect early AKI (42). The 
NephroCheck Test analyzes both tissue inhibitor of metalloproteinase-2 (TIMP-2) and 
insulin-like growth factor binding protein 7 (IGFBP7) and is an example of a combined test 
with higher sensitivity than if these two parameters were analyzed separately. These 
molecules are markers for cellular arrest and are thought to serve as very early indicators of 
AKI. In the context of sepsis, the NephroCheck Test predicted KDIGO stage 2 or 3 AKI 
within 12 hours following testing (43,44). 
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GLOMERULAR FILTRATION RATE 
GFR is the total amount of blood that is filtered through all glomeruli in the kidneys per 
minute. The GFR is dependent on the filtration surface area, permeability of the glomeruli, 
and net filtration pressure. GFR can be measured using substances that are metabolically 
inert, freely filtered, and not reabsorbed or secreted in the tubules. No such endogenous 
substance has been identified; instead, exogenous substances (e.g., inulin) are the gold 
standard for GFR measurement. Calculation of GFR is based on the blood and urine 
concentration of the substance after administration (35). However, the use of exogenous 
substances is expensive and time-consuming and carries a risk of complications. Of the many 
important renal functions, GFR can be used to assess overall renal function and determine the 
stage of CKD. It is also used for dose adjustment of medications with renal elimination (45). 
GFR is usually expressed in milliliters per minute per 1.73 m2. The area of 1.73 m2 is the 
average surface area of an adult. An individual’s true GFR can thereby be overestimated or 
underestimated in a very small or large individual, respectively. The GFR varies according to 
age, sex, body size, and ethnicity. A normal resting GFR is around 120 to 130 
mL/min/1.73m2 in young adults and declines from this age around 9 mL/min/1.73m2 per 
decade (46–48). 
The SCr concentration is in balance with GFR, and the properties of creatinine make it 
suitable for estimation of GFR. However, it is not possible to directly transform the SCr 
concentration into GFR because of individual differences in creatinine turnover, which is 
mainly dependent on total muscle mass. To overcome this problem, mathematical equations 
have been developed using both the SCr concentration and body composition parameters 
(Table 3). Estimated GFR is calculated from its inverse relationship with the SCr 
concentration adjusted for non-renal variables that influence the SCr concentration, such as 
age, sex, and ethnicity. New formulas also include other biomarkers such as cystatin C. 
Cystatin C has properties similar to those of creatinine, and GFR estimations using both SCr 
and cystatin C are reportedly more accurate than the use of either one alone (45). 
Many consider that measured GFR is more clinically important than the estimated GFR 
because it provides the “true” value of the GFR. This is thought to be especially important in 
the long-term monitoring of renal function because among other parameters, the muscle mass 
of patients with CKD can vary substantially. However, this has been questioned because 
parameters used in GFR measurement also vary (e.g., inulin vs. iothalamate), and the 
measured GFR does not consistently improve prediction of renal-related outcomes (49). 
Estimated GFR is considered suitable to monitor changes in renal function in many cases 
(35). 
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Table 3. Overview of some of the most frequently used equations for estimation of GFR in adults.  
Name Year 
introduced 
Variables 
included 
Comments  
Cockcroft-
Gault formula 
(50) 
1976 SCr, age, sex, 
weight 
Generally overestimates GFR around 10 to 20 % since it 
estimates creatinine clearance. Overestimates GFR in 
obese, and underestimates in elderly (51,52). Accurate in 
individuals <65 years with GFR 20 to 60.  
MDRD Study 
Equation (53) 
1999 SCr, age, sex, 
urea, albumin, 
ethnicity 
Have been updated/modified several times. 
Underestimates GFR among patients with GFR >60. 
More precis than equation above. The study material did 
not include individuals >70 years of age. 
Lund-Malmö-
1 equation 
(54) 
2007 SCr, age Mostly validated in Swedish Caucasians. The Lund-
Malmö-2 equation includes lean body mass which 
removes bias in obese and underweight men (45). 
CKD-EPI 
formula (55) 
2009 Age, sex, SCr, 
ethnicity 
Comparable with MDRD among individuals with 
GFR<60. More precise among individuals with GFR >60.  
CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration, GFR = glomerular filtration rate, MDRD 
= Modification of Diet in Renal Disease, SCr = serum creatinine. 
 
INCIDENCE AND OUTCOMES 
The reported worldwide incidence of AKI has increased during the last few decades (2). In 
some parts of the world, this increased incidence may be explained by the aging population 
and increased number of individuals with multiple diseases. The increased use of radiological 
examinations with iodinated contrast agents and the use of nephrotoxic drugs might also 
partly explain the increasing incidence of AKI. Variations in the incidence of AKI and 
complications associated with AKI might also be explained by the plentiful definitions of 
AKI that are in use worldwide. It is also possible that increased awareness and reporting of 
AKI among clinical practitioners have led to increased incidences in studies using diagnostic 
codes. 
AKI is common in the hospital setting. Approximately 20% of hospitalized adults and 30% of 
hospitalized children develop AKI (2). The frequency of AKI varies depending on the clinical 
setting and is most common in patients who are critically ill, have undergone cardiac surgery, 
or have been hospitalized for heart failure, with a pooled incidence of around 32%, 32%, and 
24% respectively (2). 
The mortality associated with AKI is high but depends on the clinical context. A large meta-
analysis by Susantitaphong et al. has investigated the pooled AKI-associated mortality in 
several clinical contexts (2). In 91 of the 106 included studies the duration of follow-up was 
<3 months. The highest AKI-associated mortality was among patients with trauma, critical 
illness, and hematologic or oncologic disease, in whom the mortality is around 25% to 30% 
(2). The AKI-associated mortality among patients who have undergone cardiac surgery was 
around 8% (2). AKI is also associated with the development of CKD, longer intensive care 
unit and hospital stays, and increased health care costs (3). Approximately 5% to 20% of 
critically ill patients who require dialysis due to AKI remain dialysis-dependent at hospital 
discharge (3,56). Around 5% of patients who develop stage 2 to 3 AKI after isolated CABG 
progress to end-stage renal disease requiring dialysis within a period of 5 years after surgery 
(4). 
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CAUSES OF ACUTE KIDNEY INJURY 
Traditionally, the etiologies of AKI have been divided into three categories: prerenal, renal, 
and postrenal AKI (Figure 2). This categorization is used to help the clinician identify the 
cause of AKI. Depending on the extent of the insult, any of these three categories of AKI can 
cause loss of renal functional mass and CKD. The combination of prerenal and renal AKI is 
common and may occur, for example, in patients with sepsis or those undergoing cardiac 
surgery. AKI is seldom symptomatic; clinical signs and symptoms are related to the 
underlying cause. The most common etiologies of AKI are presented in Figure 2. (57) 
 
 
Perioperative AKI 
Perioperative AKI is defined as rapid deterioration of renal function during or shortly after 
surgery. The incidence of perioperative AKI is most common in cardiac, orthopedic, and 
abdominal surgery with an incidence of around 25%, 22%, and 20%, respectively (59). The 
Figure 2. 
Schematic overview of the most common etiologies of AKI divided into prerenal, renal, 
and postrenal causes.  
5-ASA = 5-aminosalicylic acid, ACEi = Angiotensin converting enzyme inhibitor, ARB 
= angiotensin receptor blocker, HBV = hepatitis B virus, HCV = hepatitis C virus, 
NSAID = nonsteroidal anti-inflammatory drug, PPI = proton pump inhibitor, SLE = 
systemic lupus erythematosus. 
Figure from Hertzberg et al. 2016 (58). Reprinted and modified with permission from 
Läkartidningen. 
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incidence is higher in surgical patients with several risk factors for AKI, such as in patients 
undergoing gastric bypass surgery or hip fracture surgery (59). The incidence is also 
dependent on the specific surgical procedure being performed. The mechanisms for 
perioperative AKI are often multifactorial. Important factors in perioperative AKI are 
hypoperfusion, venous congestion, nephrotoxin exposure, inflammation, and oxidative stress 
(Figure 3) (60). Risk factors for perioperative AKI can be divided into three categories: 
preoperative demographic characteristics and comorbidities, acute preoperative conditions 
and nephrotoxin exposure, and intraoperative procedures and complications. Patient 
characteristics and comorbidities associated with AKI include high age, female sex, CKD, 
diabetes, congestive heart failure, chronic obstructive pulmonary disease, peripheral vascular 
disease, and high body mass index (21,59,61,62). Preoperative conditions such as 
dehydration, anemia, and acute decompensated heart failure are also associated with AKI 
(59). Perioperative risk factors for AKI include hypotension, hypovolemia, blood loss, 
anemia, blood transfusion, and cardiopulmonary bypass (8). 
In cardiac surgery, much attention has been directed toward the cardiopulmonary bypass 
circuit (63). This circuit is thought to cause ischemia/reperfusion injury, activation of 
inflammatory pathways due to exposure to artificial surfaces, hemolysis with subsequent 
release of heme and labile iron, and generation of reactive oxygen species (63). The lack of 
pulsatile blood flow may be another contributing factor (59). Prolonged durations of 
cardiopulmonary bypass, aortic cross-clamping, and deep hypothermic circulatory arrest are 
other risk factors for AKI in cardiac surgery. These factors are also associated with low 
cardiac output syndrome (59,64). Cardiac surgery without cardiopulmonary bypass (off-
pump surgery) has been thought to reduce the risk of AKI. A meta-analysis of randomized 
controlled trials showed a lower incidence of AKI but no decreased need for renal 
replacement therapy in patients who underwent off-pump compared to on-pump surgery (65). 
These results are consistent with other studies showing that off-pump surgery does not reduce 
the risk of dialysis within 30 days or 1 year (66–68). However, Chawla et al. investigated 
differences in the benefits of off-pump surgery with respect to preoperative renal function and 
found that off-pump surgery in patients with CKD undergoing CABG was associated with a 
lower risk of death and need for renal replacement therapy (69). Blood loss, anemia, and 
blood transfusions are related to perioperative AKI in patients undergoing cardiac surgery. 
The age of the red blood cells is not associated with adverse outcomes, including AKI (70). 
Perioperative administration of iodinated contrast, aminoglycosides, angiotensin-converting 
enzyme inhibitors, and loop diuretics is also associated with AKI in patients undergoing 
cardiac surgery (64). 
The rate of AKI after cardiac surgery is strongly correlated with the surgical procedure. 
CABG is associated with the lowest incidence of AKI, while valve replacement, especially 
with concurrent CABG, is associated with the highest incidence of AKI (59). 
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PREVENTION AND TREATMENT OF AKI 
The principles of treatment for AKI can be divided into three categories: treatment of the 
underlying cause, optimization for recovery, and specific AKI treatment. This text will briefly 
mention the two latter categories and cover the most frequently discussed interventions. 
Optimization for recovery 
Optimization for AKI recovery involves volume and hemodynamic optimization, treatment 
of electrolyte disturbances, and dose adjustment or discontinuation of medications that are 
nephrotoxic or are dependent on renal elimination (21,71). 
Hypoperfusion is an important factor in many patients with AKI, and hemodynamic 
optimization is a cornerstone of AKI treatment. The goal is to maintain adequate renal 
perfusion that allows for sufficient glomerular filtration and oxygenation of the renal tissue. 
The optimal blood pressure target in patients with AKI remains unknown, and few studies 
have investigated this issue. In noncardiac surgery populations, periods of a mean arterial 
pressure <55 to <60 mmHg have been associated with an increased risk for AKI (72,73). A 
Figure 3.  
Schematic illustration of 
factors contributing to 
perioperative AKI. 
AKI = Acute kidney injury, 
RAAS = Renin angiotensin 
aldosterone system. 
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study on patients undergoing CABG showed that a mean target arterial pressure of 75 to 85 
mmHg had no protective effect on the risk of AKI compared with a target pressure of 50 to 
60 mmHg (74). In contrast, a study of patients with vasodilatory shock after cardiac surgery 
showed that restoration of the mean arterial pressure from 60 to 75 mmHg using 
norepinephrine was associated with an increased GFR and improved renal oxygen delivery 
(75). To be noted, there are likely individual differences and higher blood pressures might be 
needed in patients with chronic hypertension and possibly in patients with AKI with edema 
within the renal capsule. 
The importance of fluid overload and venous congestion in patients with AKI has gained 
increasing attention. The kidneys are surrounded by a relatively inflexible capsule. Excessive 
fluid therapy in combination with AKI can cause high intracapsular pressure secondary to 
interstitial edema and a subsequent decrease in renal perfusion (76–78). I an animal model of 
ischemia-induced AKI, there was an association between subcapsular pressure and degree of 
AKI. Also, decapsulation improved renal function (77). The clinician must therefore 
administer fluid therapy to ensure adequate cardiac output while avoiding fluid overload. 
Venous congestion also decreases renal perfusion and is thus one of many problems in the 
panorama of the failing heart (cardiorenal syndrome [CRS] type 1). Various vasoactive drugs 
have been evaluated in favor of stricter fluid therapy. A possible treatment for patients with 
AKI and venous congestion is inotropic therapy. A study on the inotropic and vasodilating 
drug levosimendan showed an increased cardiac index, stroke volume index, renal blood 
flow, and GFR after cardiac surgery (79).  
The choice of fluid in treatment of AKI has been widely discussed. There is evidence that 
fluids with a high chloride content (e.g. sodium chloride 0.9%) may be harmful to the kidney 
(80). An increased chloride concentration at the macula densa has been shown to increase 
tubuloglomerular feedback, causing vasoconstriction of the preglomerular arterioles and a 
subsequent decrease in renal perfusion (81). However, a recent randomized trial revealed no 
increased risk of AKI in patients treated with sodium chloride 0.9% compared with a 
buffered solution (82).  
Synthetic colloids are used for intravascular expansion. A possible benefit of colloids is that 
more of the fluid remains in the blood vessels and does not enter the interstitium. Studies 
have shown that the synthetic colloid hydroxyethyl starch is associated with an increased risk 
of AKI, dialysis, and death compared with crystalloid solutions (83,84). Other colloids such 
as dextrans and gelatins have not been widely investigated, although some evidence points 
toward effects similar to those of hydroxyethyl starch (85,86). Albumin solutions are not 
associated with AKI but are expensive (87). There have not been demonstrated a benefit of 
using albumin compared to crystalloid solutions for volume expansion in the prevention of 
AKI (87,88). 
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Specific AKI prevention and treatment 
Furosemide is a diuretic that blocks energy-consuming sodium channels in the renal tubules 
and thereby has potential renoprotective qualities by decreasing oxygen consumption and 
increasing washout of nephrotoxic molecules (89,90). However, the use of diuretics is 
associated with a risk of hypovolemia. Furosemide also acidifies the urine, which potentially 
increases the formation of obstructive proteins in certain cases such as in hemolysis and also 
increase the activity of reactive oxygen species (63,89). Studies have not shown that 
furosemide prevents AKI or improves AKI outcomes except in patients with fluid overload 
(89). The administration of furosemide to prevent AKI after cardiac surgery and exposure to 
contrast has been associated with higher risk of AKI (91,92). 
Acetylcysteine has not been shown to prevent AKI in patients who have undergone cardiac 
surgery or in those with sepsis (93–95). Studies on acetylcysteine to prevent contrast-induced 
AKI have provided conflicting results, but meta-analyses have identified a tendency toward a 
protective effect, especially in high-risk patients (96,97). Many guidelines state that there 
might be a protective effect of acetylcysteine, but it is not generally recommended. Hydration 
with a isotonic crystalloid solution is the primary preventive medication against contrast-
induced AKI (98–100). 
Statins have not been found to prevent AKI in patients undergoing cardiac surgery and have 
even been associated with a higher risk of AKI in the intensive care setting (101–104). In 
contrast, statins have shown a possible preventive effect against contrast-induced AKI 
(105,106). Statins are not recommended for AKI prevention or treatment because of 
conflicting results (21). 
Remote ischemic preconditioning is performed to induce ischemia in an extremity by short 
episodes of external compression. The hypothesis is that the ischemia will activate ischemic-
protective mechanisms in remote organs such as the kidneys by processes such as cell-cycle 
arrest in the renal tubules. However, study results have been inconsistent. In summary, there 
has been found a small preventive effect against contrast-induced AKI and a small to 
nonexistent preventive effect against AKI after cardiac surgery (107–113). 
The timing of dialysis initiation in patients with AKI has been widely discussed. The most 
recent randomized trial (ELAIN trial) showed that early initiation of renal replacement 
therapy in critically ill patients was associated lower mortality and duration of renal 
replacement therapy (114). The former AKIKI trial showed that early initiation of renal 
replacement therapy had no benefits (115). However, early dialysis initiation in AKIKI 
resembled late initiation in ELAIN, which might explain the contradictory results.  
THE CARDIORENAL SYNDROME 
Heart and kidney function are closely interconnected. Their physiological interaction 
maintains the body’s hemodynamic homeostasis. Acute or chronic disease in one of these 
organs can induce acute injury or chronic worsening of function in the other. This co-
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pathology between the heart and kidney has been described as the CRS, which is sub-
classified according to which organ is primarily diseased and within what time frame the 
interaction is occurring (Table 4) (116). Both the heart and kidneys share several risk factors 
for disease. For example, hypertension, diabetes mellitus, and peripheral vascular disease are 
risk factors for both heart failure and CKD (29,117–119). 
 
Table 4. Description of the cardiorenal syndromes (116).  
CRS type Name Description Example 
I Acute cardio-renal 
syndrome 
Acute worsening of cardiac function 
leading to AKI 
Acute de-compensated 
heart failure 
II Chronic cardio-renal 
syndrome 
Chronic cardiac dysfunction leading to 
kidney dysfunction 
Congestive heart failure 
III Acute reno-cardiac 
syndrome 
AKI leading to heart injury or 
dysfunction. 
AKI unspecified 
IV Chronic reno-cardiac 
syndrome 
CKD leading to heart injury, disease or 
dysfunction. 
CKD 
V Secondary cardio-
renal syndromes 
Systemic disorders causing both cardiac 
and renal dysfunction 
Sepsis 
AKI = acute kidney injury, CKD = chronic kidney disease, CRS = cardiorenal syndrome. 
 
Cardiorenal syndrome type III 
A few animal studies have investigated the acute effects of AKI on the heart. Robinson et al 
showed a reduced response to cardiac inotropes in rats with glycerol-induced AKI (120). 
Kelly studied the effects of renal artery occlusion in rats and found increased blood levels of 
tumor necrosis factor-α and interleukin-1, increased cardiac leukocyte infiltration, and 
echocardiographic changes in left ventricular function after 48 hours (121). Sumida et al. 
cross-clamped the renal arteries in mice for 30 minutes. After 72 hours, the authors observed 
cardiomyocyte apoptosis, mitochondrial fragmentation, increased expression of tumor 
necrosis factor-α, and cardiac dysfunction on echocardiography (122). Other reported effects 
of AKI include fluid overload, electrolyte imbalances, acidemia, uremic toxins, activation of 
the sympathetic nervous system, and activation of the renin-angiotensin-aldosterone system 
(123). 
Cardiac depression is common in patients with severe sepsis and septic shock (124). Signs of 
reduced left ventricular contractility are found on echocardiography in such patients; this 
phenomenon is called septic cardiomyopathy (124). Studies have repeatedly identified tumor 
necrosis factor-α and interleukin-1 as important endogenic mediators (125). These 
inflammatory mediators were also identified in the animal models of CRS type III established 
by Kelly and Sumida et al. (122). It is possible that AKI-induced inflammation affects the 
heart via pathways similar to those in septic cardiomyopathy. However, the clinical 
importance of CRS type III is largely unknown. In human AKI studies, it is often difficult to 
determine which organ was affected first. Many studies might have described CRS types III 
and I. It is also possible that such injuries arise simultaneously and continue in a vicious 
circle.  
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AIMS OF THE THESIS 
 
The overall aim of this thesis was to further investigate the risk factors for and outcomes of 
AKI in patients undergoing cardiac surgery. The specific aims were: 
 
Study I To study the association between treatment with the antibiotic prophylaxis 
teicoplanin in cardiac surgery and the risk of developing perioperative AKI. 
 
Study II To study the association between preoperative type 1 diabetes mellitus and type 
2 diabetes mellitus, respectively, and the risk of developing AKI after CABG. 
 
Study III To study the association between AKI after CABG and the long-term risk for a 
first hospitalization for heart failure.  
 
Study IV To study the association between minimal increases of 0 to 26 µmol/L in 
postoperative SCr concentrations and the long- and short-term risk of death or 
the combined outcome of long-term mortality, heart failure, myocardial 
infarction, or stroke. 
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SUBJECTS AND METHODS 
 
REGISTERS 
Personal identity number 
Since 1947, all permanent residents of Sweden have been assigned a unique personal identity 
number (PIN) (126). The PIN is a 10-digit number that is divided into 3 parts. The first six 
digits contain information on the date of birth, the next three constitute the birth number 
containing information on sex (odd numbers = men, even numbers = women), and the last 
number is a control digit generated by a modulus 10 method on the former digits (126). The 
birth number originally contained information on the county of birth, but since 1990, the 
numbers have been randomly selected. The PIN is maintained by the National Tax Board, 
and all Swedish residents are recorded in the Total Population Register (127). Those who do 
not qualify for a PIN are assigned a personal coordination number. The number is often 
described as unique, but the combination only leaves room for 500 males and 499 females on 
each birth date. This caused a shortage of PINs from 1 January to 1 July in the 1950s and 
1960s, mainly because immigrants arrived without precise knowledge of their birth date. 
Those born within the first half of the year are assigned a birth date of January 1, and those 
born in the second half of the year are assigned a birth date of July 1. Therefore, PINs are 
reused (n = 15,887 in 2009) (126). The reuse of PINs is strictly controlled, and PINs that are 
reused are mainly those that were assigned to an individual earlier but were never used or 
were used for only a short time because of death. When extracting or merging data from 
registers, reused numbers can cause scenarios such as double death dates or double cancer 
diagnoses. 
Studies III and IV included the outcomes heart failure, myocardial infarction, and stroke 
obtained from the National Patient Register. The date of hospital discharge is included with 
these diagnoses. This minimizes the risk of a double diagnosis because the former owner of 
the PIN likely developed the diagnosis before the study follow-up of the new owner. 
The National Board of Health and Welfare used PINs to merge the two datasets used in 
Studies II to IV after approval from the local ethics committee in Stockholm. The registers 
used for Studies I to IV are listed in Table 6. 
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SWEDEHEART 
All patients undergoing cardiac surgery in Sweden are registered in the Swedish Heart 
Surgery Register (128,129). This register was established in 1992 and includes all eight 
cardiac surgery sites in Sweden. It includes demographic, administrative, and perioperative 
data (130). In 2009, the Swedish Web-system for Enhancement and Development of 
Evidence-based care in Heart disease Evaluated According to Recommended Therapies 
(SWEDEHEART) was created by merging five quality registers on cardiac care: RIKS-HIA, 
the register on myocardial infarction care; SCAAR, the register for coronary angiography and 
percutaneous coronary intervention; SEPHIA, the register for secondary prevention following 
coronary intensive care; the percutaneous valve register; and the Swedish Heart Surgery 
Register (128). SWEDEHEART is financed by the local health care provider (Swedish 
Association of Local Authorities and Regions) (128).  
The data quality of parts of SWEDEHEART is continually evaluated (128). Each year, a 
monitor randomly visits approximately 30 of the 74 hospitals and randomly selects about 30 
patients for comparison of the data in SWEDEHEART with the data in the medical records 
(129). In 2007, RIKS-HIA exhibited 96% agreement with the medical records (128). 
The (Swedish) National Patient Register 
The National Patient Register was founded by the National Board of Health and Welfare in 
1964 and has covered all of Sweden since 1987 (131). The register contains patient data (PIN, 
age, place of residence), geographical data (county, hospital/clinic), administrative data 
(locations and dates of admission and discharge), and medical data (primary and secondary 
discharge diagnoses, and performed procedures) (131). The diagnoses and performed 
procedures in the National Patient Register are classified according to the World Health 
Organization International Classification of Diseases (ICD). 
Data on the outcome variables heart failure, myocardial infarction, and stroke in Studies III 
and IV were extracted from the National Patient Register. The validity of these diagnoses 
have been evaluated. Heart failure as a primary discharge diagnosis has been shown to be 
correct in 88% of cases (132,133). The diagnosis of myocardial infarction is correct in 98% to 
100% of cases, and the proportion of myocardial infarctions identified through the register 
compared to various data sources ranges from 77% to 92% (133,134). The diagnosis of stroke 
is correct in 70% to 99% of cases, and the proportion of myocardial infarction identified 
through the register ranges from 84% to 95% (133). 
The Cause of Death Register  
The Cause of Death Register was founded by the National Board of Health and Welfare in 
1954 with the aim of describing causes of death and following the trends of mortality from 
certain causes in Sweden (135). It registers all deceased Swedish residents and contains 
information on geographical data, age, time of death, and cause of death coded according to 
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the ICD (135). Since 2011, the register has also included individuals that are not Swedish 
residents but who died in Sweden. 
The Swedish National Diabetes Register 
In 1996, the Swedish Society of Diabetology initiated the Swedish National Diabetes 
Register with the main aim of reducing morbidity secondary to diabetes. This register is 
designed to compare the clinical results among all diabetes care units (136). The register 
contains data on demographics, the duration of diabetes, treatment indications and modalities, 
cardiovascular risk factors, and complications of diabetes (136,137). After comparison with 
the Prescribed Drug Register in 2014, the national coverage of the National Diabetes Register 
reached 90% (138). The validity of the diagnosis of T1DM was previously found to have 
97% accuracy (139). 
The Swedish Renal Register 
The active care of uremia was started to be registered by the Swedish Registry for Active 
Treatment of Uremia in 1991. The register was later merged with other Swedish renal 
registers to become the Swedish Renal Register (140). All patients with end-stage renal 
disease having renal replacement therapy or receiving a kidney transplant are expected to be 
reported into the register. The prevalence is ≈1000 per 1000 000 individuals in Sweden. All 
units that carry out renal replacement and kidney transplantation in Sweden report to the 
register (141). 
The longitudinal Integration database for health Insurance and labor market 
studies 
Since 1990, the Longitudinal Integration Database for Health Insurance and Labor Market 
Studies (LISA) has included all Swedish residents ≥16 years of age. The owner of the register 
is Statistics Sweden (Swedish name: Statistiska Centralbyrån), and the register is updated 
annually. The register contains information on employment, income, residence, and education 
(142).  
The Total Population Register 
Since 1968, Statistics Sweden has run the Total Population Register (Swedish name: 
Registret över toalbefolkningen). It contains data on sex, civil status, place of birth and 
residence, citizenship, and migration status (143,144). Since 2000, only those qualifying for a 
PIN have been included in the register (126). All deceased Swedish residents are reported in 
the register on a monthly basis.   
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Table 5 summarizes the study design and outcome measures of the studies in this thesis. The 
variables used in the thesis are summarized in Table 6. 
 
Table 5. Methodological overview of studies I to IV 
 Study I Study II Study III Study IV 
Running 
title 
Teicoplanin and risk 
for AKI 
Diabetes and risk for 
AKI 
AKI and risk for 
heart failure 
Minimal creatinine 
changes 
Design Observational cohort study Nationwide observational cohort study 
Cohort 
Adults, cardiac 
surgery, at 
Karolinska 
University Hospital 
2010 to 2013 
Adults, isolated 
CABG in Sweden 
2003 to 2013 
Adults, isolated CABG in Sweden 2000 to 
2008 
Number of 
patients 2809 36 106 24 018 25 686 
Source 
Cohort: 
Local cardiac surgery 
register (part of 
SWEDEHEART) 
 
Additional data: 
Medical records 
Cohort: 
SWEDEHEART 
 
Additional data: 
National Patient 
Register 
NDR 
Swedish Renal 
Register 
LISA 
Cohort: 
SWEDEHEART 
 
Additional data: 
National Patient 
Register 
Cause-of-death 
register 
Cohort: 
SWEDEHEART 
 
Additional data: 
National patient register 
Total population 
register 
Exposure(s) Teicoplanin T1DM, T2DM 
AKI, three stages: 
1: 26-44 µmol/L 
2: 44-88 µmol/L 
3; >88 µmol/L 
AKI, three groups: 
1: 0 to 26 µmol/L 
2: 26 to 44 µmol/L 
3: >44 µmol/L 
Outcome(s) 
AKI according to 
AKIN stage 1:  
SCr increase ≥26 
µmol/L or ≥50%. 
AKI according to 
AKIN stage 1: SCr 
increase ≥26 µmol/L 
or ≥50%. 
Heart failure 
Long-term mortality, 
30-day mortality,  
combined end-point of 
heart failure, mycardial 
infarction, stroke, or 
death 
Follow-up Postoperative stay Until Dec 31, 2013 Until Dec 31, 2008 
Short-term mortality: 
Until 30 days after 
surgery. 
Long-term mortality: 
Until Dec 2011. 
Cardiovascular 
outcomes:  
Until Dec 31, 2008 
Statistical 
analysis 
Logistic regression 
 
Logistic regression 
 
Survival analysis 
(Cox regression) 
Logistic regression 
Survival analysis (Cox 
regression) 
AKI = acute kidney injury, CABG = coronary artery bypass grafting, LISA = Longitudinal Integration 
Database for Health Insurance and Labor Market Studies, NDR = National Diabetes Register, 
SWEDEHEART = Swedish Web-system for Enhancement and Development of Evidence-based care in Heart 
disease Evaluated According to Recommended Therapies, T1DM = type 1 diabetes mellitus, T2DM = type 2 
diabetes mellitus. 
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Table 6. Origin of variables used in Studies I to IV 
Variable Description/Definition Used in study a 
  I II III IV 
SWEDEHEART 
Age      
Sex      
Weight      
Length      
Preoperative serum creatinine b Usually taken within 24 hours before 
surgery.  
    
Postoperative serum creatinine b The highest value during postoperative stay.     
Preoperative dialysis      
Diabetes mellitus Defined as ongoing treatment with insulin or 
oral hypoglycemic drugs 
    
Left ventricular ejection fraction      
Chronic obstructive pulmonary disease Defined as ongoing treatment     
Peripheral vascular disease Defined as previous surgery on carotid or 
iliac artery, abdominal aorta or presence of 
claudication  
    
Current smoking Self reported     
Hypertension Defined as ongoing treatment     
Hyperlipidemia Defined as ongoing treatment     
Preop. Hemoglobin concentration      
Prior stroke      
Recent myocardial infarction within 90 
days 
     
Prior PCI      
EuroSCORE      
Year of surgery      
Waiting time to surgery      
Emergent surgery  Surgery <24 hours from decision     
Type of surgery      
Previous cardiac surgery      
Use of internal thoracic artery      
Number of CABG grafts      
Number of arterial CABG grafts      
Radial artery CABG graft      
Bilateral internal mammary arteries      
Cardiopulmonary bypass       
Deep hypothermic circulatory arrest      
Death within 30 days      
Postoperative Creatine kinase MB      
Length of hospital stay      
Deep sternal wound infection       
Reoperation      
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Table 6. (Continued) 
Variable Description/Definition Used in study a 
  I II III IV 
National Patient Register c 
Heart failure ICD-8: 427 
ICD-9: 428 
ICD-10: I50 to I50.9 
    
Prior Stroke ICD-7: 330-334 
ICD-8 & ICD-9: 430-438 
ICD-10: I60-I69.9 
    
Prior Mycardial infarction ICD-7: 420 
ICD-8 & ICD-9: 410 
ICD-10: I21 to I21.9 
    
Chronic Obstructive Pulmonary Disease ICD-7: 502 
ICD-8 & ICD-9: 490-496 
ICD-10: J44 to J44.9 
    
Alcohol abuse ICD-9: 291, 303, 571 
ICD-10: F10 to F10.9, K70 to K70.9 
    
Peripheral vascular disease ICD-9: 440 to 446 
ICD-10: I65 to I65.9, I71 to I71.9, I73.8, 
I73.9 
    
Atrial fibrillation ICD-10: I48 to I48.9     
Hypertension ICD-9: 401 to 405 
ICD-10: I10 to I15.9 
    
Hyperlipidemia ICD-9: 272 
ICD-10: E78 to E78.9 
    
Cause-of-death register  
Date of death      
National Diabetes Register 
Type 1 diabetes      
Type 2 diabetes      
Duration of diabetes      
HbA1c      
Type 2 diabetes treatment regimens      
Svenskt njurregister 
End stage renal disease      
LISA Statistics Sweden 
Education      
Birth region      
Martial Status      
The Total Population Register 
Death date      
Medical records 
Teicoplanin treatment      
a Variables used in studies are marked with yellow. 
b Analyzed according to Jaffé until 2005, thereafter enzymatic method. 
c ICD-7 was used 1958-1968, ICD-8 & 9 was used in 1969-1996, and ICD-10 was used from 1997 until 
today.  
CABG = Coronary artery bypass grafting, EuroSCORE = European System for Cardiac Operative Risk 
Evaluation, HbA1c = hemoglobin A1c, ICD = International Classification of Diseases, PCI = Percutaneous 
coronary intervention. 
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DATA COLLECTION AND STUDY POPULATION 
Studies I to IV complied with the Declaration of Helsinki and were approved by the regional 
human research ethics committee in Stockholm, Sweden. 
Study I 
The cohort of Study I included all patients who underwent cardiac surgery from 1 January 
2010 to 31 July 2013. On 6 December 2011, the institutional policy was changed and 
teicoplanin was added to the standard antibiotic prophylaxis regimen. This continued until 31 
July 2013, when this change was reversed. Therefore, most of the patients treated with 
teicoplanin (exposed group) underwent surgery after December 6, 2011. The exclusion 
criteria for Studies I to IV are presented in Figure 4. Information on the patients was extracted 
from the local Heart Surgery Register at Karolinska University Hospital. Data on teicoplanin 
treatment were retrieved from the medical records. 
Study II 
Study II included all patients who underwent primary nonemergent isolated CABG in 
Sweden from 1 January 2003 to 31 December 2013. The exclusion criteria and number of 
excluded patients are shown in Figure 4. The cohort was retrieved from SWEDEHEART and 
cross-linked with the National Diabetes Register, the National Patient Register, LISA, and the 
Total Population Register. The origins of the included variables are shown in Table 6. The 
registers were linked by the National Board of Health and Welfare using PINs. The data was 
de-identified after linkage and the key was erased. 
Study III and IV 
In Studies III and IV, all patients who underwent CABG in Sweden from 1 January 2000 to 
31 December 2008 were eligible for inclusion. The cohort was retrieved from 
SWEDEHEART and cross-linked with the National Patient Register and Cause of Death 
register using PINs. The included variables are shown in Table 6. The registers were linked 
by the National Board of Health and Welfare using PINs. The data was de-identified after 
linkage and the key was erased. The exclusion criteria and number of excluded patients are 
shown in Figure 4. 
 37 
  
Figure 4.  
Exclusion criteria for Studies I to IV.  
eGFR = estimated glomerular filtration 
rate, CABG = coronary artery bypass 
grafting,  
Figures adopted from the manuscript of 
Studies I to IV and modified. 
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Exposure measures 
Study I 
The exposure in Study I was treatment with teicoplanin. On December 6, 2011, the 
institutional policy on antibiotic prophylaxis regimen was changed, and teicoplanin was 
added to the standard therapy which was cloxacillin. This regimen was as follows: 2 g of 
cloxacillin administered immediately before surgery, immediately after cardiopulmonary 
bypass, and every 8 hours thereafter until 48 hours postoperatively. In patients allergic to 
penicillin, cloxacillin was replaced with 600 mg of clindamycin. Teicoplanin was given as a 
single dose intravenously just before the start of the operation. The dose was 400 mg for 
patients weighing <80 kg and 600 mg for patients weighing >80 kg. 
Study II 
The exposure in Study II was either T1DM or T2DM. Information on diabetes was retrieved 
from the National Diabetes Register. T1DM was defined as an onset of diabetes before 30 
years of age and treatment with insulin as the only glucose-lowering medication, which is a 
so-called epidemiological definition. T2DM was defined as isolated treatment with either diet 
or oral hypoglycemic medication, or onset of diabetes at >40 years of age with insulin 
treatment with or without oral hypoglycemic medication. Patients not included in the 
National Diabetes Register were defined as non-diabetics. 
Studies III and IV 
AKI was defined according to the absolute increase in post- compared to preoperative SCr 
concentration. The preoperative SCr was normally measured within 24 hours before surgery, 
and the postoperative SCr used was the highest value measured during the index 
hospitalization which in a previous study was the highest level within 48 hours of surgery in 
92% of AKI cases (145). 
The exposure in Study III was defined according to the three stages of AKI: stage 1, increase 
of 26 to 44 µmol/L; stage 2, increase of 44 to 88 µmol/L; and stage 3, increase of >88 µmol/L 
in postoperative SCr concentrations. This definition has been used in previous studies and 
was based on the AKIN criteria for stage 1 (26 µmol/L) and traditional arbitrary definitions 
(0.5 mg/dL = 44 µmol/L, 1 mg/dL = 88 µmol/L) (19,146). We also performed a secondary 
analysis with the same multivariable model but defined the exposure AKI according to the 
AKIN criteria: stage 1, increase of 26 to 44 µmol/L or relative increase of 50% to 100%; 
stage 2, 100% to 200% increase; and stage 3, >200% increase in postoperative SCr 
concentrations. 
The exposure in Study IV was a redefined version of AKI that included minimal increases in 
postoperative SCr concentrations. The AKI stages are called AKI groups in this study to 
prevent confusion with common definitions of AKI, such as those used in the AKIN criteria. 
Three AKI groups were defined according to the increase in the SCr concentration from the 
preoperative to postoperative period: group 1, 0 to 26 µmol/L; group 2, 26 to 44 µmol/L; and 
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group 3, >44 µmol/L. The reference group had either no change or a decrease in the SCr 
concentration. 
Outcome measures 
Study I and II 
The outcome in Studies I and II was AKI, which was defined as an absolute or relative 
increase in the SCr concentration from the preoperative to postoperative period of ≥26 
µmol/L or ≥50%, respectively. This definition of the SCr increase is in line with the AKIN 
and KDIGO criteria for stage 1 (Table 1). However, the time frame differs. The preoperative 
SCr concentration was usually measured within 24 hours before surgery, and the 
postoperative SCr concentration was the highest value measured during the index 
hospitalization.  
To further investigate the impact of T1DM and T2DM on the risk of AKI in Study II, 
secondary analyses were performed according to more severe AKI definitions. Three separate 
analyses were performed using three different definitions of AKI: the original definition of 
AKI, a definition according to AKIN stage II, and a definition according to AKIN stage III 
(Figure 5). 
Study III 
The primary outcome in Study III was hospitalization for the first time with heart failure as a 
primary discharge diagnosis in the National Patient Register. Patients with a preoperative 
diagnosis of heart failure were excluded from the study. Data on hospitalization for heart 
failure were retrieved from the National Patient Register using ICD codes (Table 6). The 
secondary outcome was the combined outcome of heart failure and death. The date of death 
was retrieved from the Swedish Cause of Death Register. Follow-up started on postoperative 
day 30 and ended at the time of hospitalization for heart failure, the time of death, or the end 
of the study (31 December 2008).  
Study IV 
The primary outcome in Study IV was long-term all-cause mortality. The two secondary 
outcomes were 30-day all-cause mortality and the combined outcome of long-term all-cause 
mortality, hospitalization for heart failure, myocardial infarction, or stroke. Information on 
survival was retrieved from the Total Population Register in February 2011. Data on heart 
failure, myocardial infarction, and stroke was retrieved from the National Patient Register 
using ICD codes. Follow-up ended on 31 December 2008.  
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Generated variables 
Estimated GFR 
The estimated GFR was calculated using information on preoperative SCr concentration, age 
and sex from SWEDEHEART. In Studies I, III, and IV, the estimated GFR was calculated 
using the simplified Modification of Diet in Renal Disease (MDRD) equation (53). In Study 
II, the estimated GFR was calculated using to the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation (55). 
 
CKD-EPI equation 
Female with SCr ≤62 µmol/L: GFRCKD-EPI = 144 × (SCr/0.7)−0.329 × 0.993age [×1.159 if black] 
Female with SCr >62 µmol/L: GFRCKD-EPI = 144 × (SCr/0.7)−1.209 × 0.993age [×1.159 if black] 
Male with SCr ≤80 µmol/L: GFRCKD-EPI = 141 × (SCr/0.9)−0.411 × 0.993age [×1.159 if black] 
Male with SCr >80 µmol/L: GFRCKD-EPI = 141 × (SCr/0.9)−1.209 × 0.993age [×1.159 if black] 
 
The simplified MDRD equation 
GFRMDRD = 186 × (SCr [µmol/L])−1.154 × age−0.203 [×0.742 if female] [×1.210 if black] 
 
Body mass index 
Body mass index was calculated using data on weight and length obtained from 
SWEDEHEART. 
Body mass index = weight (kg) / (length [cm]/100)2  
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STATISTICAL ANALYSES 
In Studies I to IV, the baseline characteristics are described using means and standard 
deviations for continuous variables and numbers and percentages for categorical variables. 
Stata versions 12 and 13 (StataCorp LP, College Station, TX, USA) was used for the 
statistical analyses in Studies I to IV. R version 3.1.1 (R Foundation for Statistical 
Computing, Vienna, Austria) was used for data management in Study II. 
Study I 
Logistic regression was used to analyze the association between treatment with teicoplanin 
and the risk of developing AKI. ORs with 95% confidence intervals (CI) were calculated in a 
crude, adjusted for age and sex, and multivariable adjusted model. The multivariable adjusted 
model was constructed after considering all baseline characteristics presented in Table 7 and 
primary interaction terms. The final multivariable model included the variables age, sex, 
estimated GFR, left ventricular ejection fraction (LVEF), diabetes mellitus, deep hypothermic 
circulatory arrest, chronic obstructive pulmonary disease, preoperative hemoglobin 
concentration, postoperative creatine kinase MB concentration, and body mass index. All 
continuous variables (age, estimated GFR, hemoglobin concentration, body mass index, and 
creatine kinase MB concentration) were flexibly modeled using restricted cubic splines with 
three knots. Nonlinear associations with the outcome were identified by testing the null 
hypothesis that the second spline was significant at a p value of <0.05. Separate subgroup 
analyses were performed according to treatment dose, sex, estimated GFR, and type of 
surgical procedure and by excluding patients who developed a postoperative deep sternal 
wound infection. 
Study II 
Logistic regression was used to analyze the association between T1DM or T2DM and the risk 
of developing AKI. Patients without a diagnosis of diabetes comprised the reference group. 
ORs with 95% CIs were calculated. The multivariable adjusted model included all variables 
in Table 9 except duration of diabetes, hemoglobin A1c concentration, and European System 
for Cardiac Operative Risk Evaluation (EuroSCORE). The normal distribution of continuous 
variables was checked by formal analysis and visual examination. All continuous variables 
were flexibly modeled using restricted cubic splines with three knots at the 10th, 50th, and 90th 
percentiles. We checked for primary interactions. Missing data were not imputed (Table 9). 
Observations with missing data for variables included in the models were excluded. As a 
sensitivity analysis, we imputed the missing data using multiple imputation by chained 
equations for comparison with the primary results.  
We performed subgroup analyses according to the T2DM treatment regimens: dietary 
treatment only, oral hypoglycemic medication, or insulin with or without oral hypoglycemic 
medication. We also performed secondary analyses for the risk of AKI according to the three 
definitions of AKI representing increasing severity of AKI (Figure 5). 
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Study III 
The association between AKI and the risk of first hospitalization for heart failure was studied 
using Cox proportional hazards regression (147). Hazard ratios with 95% CIs were calculated 
according to each stage of AKI compared with patients without AKI. Patients who died 
during follow-up were censored at the date of death. Those who did not develop heart failure 
and were alive at the end of follow-up (31 December 2008) were censored on this date. A 
multivariable model was constructed after considering all baseline characteristics. Age, sex, 
and estimated GFR was planned to be included from the start because we considered them to 
be of clinical importance in studies of AKI. Further variables were included using a manual 
stepwise forward and backward selection procedure and including variables that influenced 
the hazard ratio by ≥0.1. We also considered primary interaction terms. The final 
multivariable model included age, sex, estimated GFR, LVEF, diabetes mellitus, and 
myocardial infarction in the past or during follow-up. The proportionality assumption was 
tested and no violation was found. In the final model, there was missing data on LVEF (8%) 
and diabetes mellitus (29%). The missing data was regarded as missing at random and were 
imputed for the final multivariable model using multiple imputation by chained equations. A 
complete case analysis including 16,002 patients was also performed.  
Study IV 
The association between the AKI groups and the primary outcome of long-term mortality was 
studied using Cox proportional hazards regression (147). Cox regression was also used for 
the secondary combined outcome of long-term mortality, hospitalization for heart failure, 
myocardial infarction, or stroke. The association between AKI groups and 30-day mortality 
was analyzed using logistic regression. A multivariable model was constructed after 
considering all baseline characteristics (Table 14). A manual forward and backward selection 
procedure was used. Variables influencing a hazard ratio of ≥0.1 were included in the 
analysis. We checked for variable interaction. All variables were virtually complete except 
three variables that contained missing data: diabetes (29%), LVEF (8.3%), and peripheral 
vascular disease (8.0)%. Missing data was imputed using multiple imputation by chained 
equations. We also performed a complete case analysis in which only patients with complete 
information on all variables included in the final statistical model were included. 
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RESULTS AND METHODOLOGICAL DISCUSSIONS 
 
STUDY I – TEICOPLANIN AND RISK FOR ACUTE KIDNEY INJURY 
Results 
In total, 2809 patients were included, and 62% patients were treated with teicoplanin. The 
patients’ baseline characteristics are presented in Table 7. Patients treated with teicoplanin 
had a slightly higher preoperative estimated GFR. AKI developed in 32% of patients treated 
with teicoplanin and 29% of patients not treated with teicoplanin. The results of the primary 
analysis are presented in Table 8. Subgroup analyses showed signs of a dose-dependent 
relationship in which patients treated with a 600-mg dose of teicoplanin had an OR for AKI 
of 1.34 (CI, 1.05–1.70) and patients treated with a 400-mg dose had an OR for AKI of 1.46 
(CI, 1.15–1.84). In the subgroup analysis that included only patients undergoing isolated 
CABG, the OR for AKI was 1.31 (CI, 0.99–1.73), and in the subgroup of patients undergoing 
procedures other than isolated CABG, the OR for AKI was 1.50 (CI, 1.18–1.92). 
Discussion 
This study showed that prophylactic treatment with teicoplanin in patients who underwent 
cardiac surgery was associated with an increased risk of AKI. The results were consistent 
even after adjustment for many known risk factors for AKI. In addition, subgroup analyses 
indicated a dose-dependent relationship with higher point estimates for AKI in the high-dose 
teicoplanin group. These results suggest that the negative influence of teicoplanin on renal 
function should be considered when developing antibiotic protocols in cardiac surgery. 
A strength of this study is that the institutional policy of antibiotic prophylaxis changed from 
one day to another. This diminished the risk of selection bias. However, this study was based 
on a clinical observation that teicoplanin might cause AKI. During data collection, we found 
that 139 patients were not treated with teicoplanin during the teicoplanin period. It is possible 
that these patients were identified as those with a high risk of AKI and were therefore not 
treated with teicoplanin. Thus, this may have introduced confounding-by-indication, in this 
case meaning that treatment was withheld from the sicker patients, but given to the healthier 
ones. This suspicion is not supported by the data in Table 7, which show that patients treated 
with teicoplanin actually had a higher baseline estimated GFR. Also, we adjusted for most of 
the known risk factors for AKI, and the effect of this possible bias should have been reduced.  
Due to the reason that the unexposed and the exposed group was operated during two 
different time periods, other causes of AKI than prophylactic treatment with teicoplanin 
might have emerged. To the best of the authors’ knowledge, however, there were no changes 
in the preoperative, perioperative, or postoperative care policy that could explain the 
difference in the incidence of AKI. However, we tend to perform surgery on older and sicker 
patients. This might have resulted in a higher number of older and sicker patients in the 
 44 
teicoplanin group. On the other hand, based on the data presented in Table 7, patients treated 
with teicoplanin appear neither older nor sicker. In addition, the analysis was adjusted for 
many the known risk factors for AKI, including age. The distribution of the type of surgical 
procedure might have also differed between the exposed and unexposed groups because we 
tended to perform fewer CABG operations. In the subgroup analysis of patients undergoing 
procedures other than isolated CABG, patients treated with teicoplanin had a significantly 
increased risk of AKI. In patients undergoing isolated CABG, the lower CI was 0.99. 
Considering all results in the study, the author argues that this lower CI was most likely due 
to insufficient statistical power. Additionally, Table 7 shows no significant differences 
regarding the surgical procedures. 
The main limitation of this study is that it was not randomized. We cannot draw definitive 
conclusions regarding causality because there might have been confounding factors unknown 
to the authors that biased the association between treatment with teicoplanin and risk of AKI. 
A randomized controlled trial is needed to obtain a more definitive conclusion regarding 
teicoplanin and risk of AKI. Such study could also be designed to summarize risks and 
benefits e.g. regarding risk for infection contra risk for AKI and subsequent complications.  
 
Table 7. Baseline characteristics of the study population in study I.  
 All patients Reference group a Teicoplanin p value 
Number of patients 2809 1056 1753  
Percent of study population 100 38 62  
Age (SD), years 66 (12) 66 (12) 66 (11) 0.277 
Female sex 26% 26% 26% 0.735 
eGFR (SD), mL/min/1.73 m2 82 (22) 80 (23) 84 (21) <0.001 
Preoperative SCr (SD), µmol/L 87 (24) 88 (25) 84 (23) <0.001 
Diabetes mellitus 21% 21% 20% 0.911 
Peripheral vascular disease 8.8% 8.6% 9.0% 0.728 
Hemoglobin concentration (SD), 
g/L 137 (15) 136 (15) 138 (15) 0.005 
COPD 9.3% 9.6% 8.8% 0.462 
Recent myocardial infarction 23% 23% 22% 0.291 
Prior stroke 7.1% 6.9% 7.6% 0.466 
Left ventricular ejection fraction     
Ejection fraction >0.5 66% 67% 65% 0.257 
Ejection fraction 0.3-0.5 28% 26% 31% 0.010 
Ejection fraction <0.3 6.1% 6.7% 4.6% 0.009 
Type of surgery     
Isolated CABG 44% 44% 43% 0.665 
Isolated valve surgery 32% 33% 31% 0.467 
Other 24% 24% 26% 0.196 
Cardiopulmonary bypass 99.5% 99.5% 99.5% 0.884 
Deep hypothermic circulatory arrest 1.9% 1.5% 2.6% 0.043 
CK-MB postop day 1 (SD), µg/L 22 (30) 22 (26) 22 (36) 0.479 
a Patients not treated with teicoplanin. 
The continuous variables age, glomerular filtration rate, and serum creatinine concentration are presented as 
mean with standard deviation. 
CABG = coronary artery bypass grafting, COPD = chronic obstructive pulmonary disease, CK-MB = creatine 
kinase Mb, eGFR = estimated glomerular filtration rate, SCr = serum creatinine, SD = standard deviation.  
Table adopted from the manuscript of Study I and modified. 
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Table 8. Risk of AKI following cardiac surgery according to teicoplanin antibiotic prophylaxis 
 All patients Reference groupa Teicoplanin 
Number of patients (%) 2809 (100) 1753 (62) 1056 (38) 
Number of events (%) 860 (31) 517 (29) 343 (32) 
  Odds Ratio (95% CI) 
Crude  1.0 1.15 (0.98-1.36) 
Adjustment for age and sex  1.0 1.20 (1.01-1.42) 
Multivariable adjustment b   1.0 1.40 (1.18-1.68) 
a Patients not treated with teicoplanin. 
b Multivariable adjustment was made for age, sex, estimated glomerular filtration rate, left ventricular ejection fraction, 
diabetes mellitus, deep hypothermic circulatory arrest, chronic obstructive pulmonary disease, preoperative hemoglobin 
concentration, postoperative creatinine kinase MB, and body mass index.  
AKI = Acute kidney injury, CI = confidence interval. 
Table adopted from the manuscript of Study I and modified. 
 
 
STUDY II - TYPE I AND TYPE II DIABETES AND RISK FOR AKI 
Results 
The study included 36,106 patients undergoing a primary nonemergent isolated CABG, of 
whom, 1.3% had T1DM and 14% had T2DM (Table 9). Patients with T1DM were younger, 
had a lower estimated GFR, were more likely to be female, and were more likely to have a 
history of heart failure than patients with no diabetes and patients with T2DM. Patients with 
T2DM had a lower estimated GFR and higher prevalence of heart failure and hypertension 
than did patients without diabetes (Table 9). AKI developed in 32% of patients with T1DM, 
20% of patients with T2DM, and 13% of patients without diabetes. The ORs for AKI in 
patients with T1DM and T2DM compared with patients without diabetes are presented in 
Table 10. Patients with T1DM had an almost five-fold higher risk of AKI, and patients with 
T2DM had a small but significantly increased risk of AKI compared to patients without 
diabetes. The results of the secondary analyses using definitions representing more severe 
AKI are presented in Figure 5. The results from the secondary analyses according to T2DM 
treatment regimens is presented in Table 11. The results of the primary analyses but with 
imputed missing values were not different from the original model. 
Discussion 
The study showed that both T1DM and T2DM were associated with an increased risk of AKI 
in patients undergoing CABG. However, the association between T1DM and risk of AKI was 
considerably much higher than the association between T2DM and AKI. The secondary 
analysis using three definitions of AKI representing increasing AKI severity showed that 
patients with T1DM and T2DM were also at risk of major declines in renal function. To the 
authors’ knowledge, this is the first study to investigate the association between subtypes of 
diabetes and the risk of AKI in patients who have undergone CABG. The results suggest that 
patients with diabetes, especially T1DM, may benefit from special consideration (e.g., 
avoidance of nephrotoxic drugs) when undergoing cardiac surgery. 
 46 
Diabetes is strongly associated with the development of atherosclerosis and microvascular 
disease (117). The risk for AKI was markedly higher in patients with T1DM than in patients 
with T2DM. One can speculate that the duration of diabetes is an important factor in this 
case. The mean duration of diabetes was 44 years in patients with T1DM and 11 years in 
those with T2DM. The subgroup analyses according to the T2DM treatment regimens are in 
line with this theory of diabetes “dose” (Table 11). Those treated with insulin had the highest 
risk for AKI, and those who underwent only dietary treatment had the lowest risk. The 
differences between the treatment groups in terms of risk for AKI are likely not due to the 
medication itself; they are more likely due to confounding by indication. It is reasonable to 
think that patients who underwent only dietary treatment had the best metabolic control and 
that those required treatment with both insulin and oral hypoglycemic medication had the 
worst. One can argue that the primary results and the treatment regimen results show a dose-
dependent/severity relationship between the diabetes and the risk for AKI.  
The main strength of this study was that we were able to subgroup patients according to 
subtype of diabetes, i.e. T1DM or T2DM. Another strength of this study was the large 
number of patients, making it possible to perform analyses according to T2DM treatment 
regimens and also different AKI definitions. A limitation was that the reference group may 
have included patients with undiagnosed T2DM, leading to misclassification of the diagnosis. 
It is likely that patients with many comorbidities tend to be screened for diabetes mellitus 
more often than healthier individuals. It is therefore possible that our group of patients with 
T2DM is on an average sicker than they would have been if we screened all patients for 
T2DM before surgery. This possible differential misclassification of the exposure can lead to 
an overestimation of the effect of T2DM and the risk for AKI. 
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Table 9. Baseline characteristics of the study population in Study II 
 All Patients 
No 
Diabetes T1DM T2DM Missing Data 
No. of patients 36 106 30 525 457 5124  
Age, years, mean (SD) 67.4 (9.2) 67.3 (9.3) 58.8 (9.3) 68.4 (8.2)  
Female sex 21% 20% 44% 23%  
Diabetes diabetes, years, mean(SD) 13.7 (12) 0 (0) 44.0 (11) 10.8 (7.7)  
HbA1c      
 IFCC (mmol/mol) <53 No data No data 9.2% 43%  
 NGSP <7.0      
 IFCC 53–73 No data No data 61% 45%  
 NGSP 7.0–8.8      
 IFCC >73 No data No data 30% 12%  
 NGSP >8.8      
BMI, kg/m2, mean (SD) 27.4 (4.1) 27.1 (4.0) 26.1 (4.2) 28.9 (4.5)  5.4% 
eGFR      
 >60 mL/min/1.73 m2 80% 81% 69% 75%  
 45–60 mL/min/1.73 m2 14% 14% 17% 16%  
 30–45 mL/min/1.73 m2 5.0% 4.5% 10% 7.5%  
 15–30 mL/min/1.73 m2 1.0% 0.8% 3.7% 1.8%  
Hypertension 41% 38% 48% 56%  
Hyperlipidemia 25% 24% 28% 31%  
Peripheral vascular disease 10% 9.5% 21% 14%  
Prior PCI 17% 16% 20% 20%  
COPD 7.9% 7.6% 5.3% 9.8%  
Prior myocardial infarction 55% 55% 53% 58%  
Heart failure 9.8% 9.1% 16% 14%  
Stroke 8.8% 8.3% 13% 12%  
Atrial fibrillation 6.4% 6.3% 2.6% 7.7%  
Left ventricular ejection fraction     2.2% 
 >50% 69% 70% 69% 65%  
 30–50% 27% 26% 27% 30%  
 <30% 4.2% 3.9% 4.3% 5.6%  
EuroSCORE, mean (SD) 4.1 (2.6) 4.0 (2.6) 3.2 (2.4) 4.5 (2.7)  
Alcohol dependency 2.3% 2.3% 1.3% 2.6%  
Birth region      
 Nordic countries 90% 90% 97% 87%  
 Other 10% 9.6% 2.8% 14%  
Education     2.4% 
 <10 years 43% 43% 35% 47%  
 10–12 years 39% 39% 44% 39%  
 >12 years 18% 18% 21% 15%  
Marital status      
 Married 66% 66% 60% 66%  
 Other 34% 34% 40% 34%  
Off-pump CABG 3.0% 3.2% 1.5% 2.0%  
No. of grafts     13% 
 1–2 19% 20% 18% 17%  
 3–4 70% 70% 72% 73%  
 >4 11% 11% 9.9% 11%  
Internal mammary artery 94% 94% 95% 93%  
Bilateral internal mammary arteries 1.1% 1.2% 0.7% 1.0%  
Radial artery 1.7% 1.7% 1.8% 1.4%  
>1 arterial graft 2.7% 2.8% 2.2% 2.3%  
BMI = body mass index, CABG = coronary artery bypass grafting, COPD = chronic obstructive pulmonary 
disease, eGFR = estimated glomerular filtration rate, HbA1c = hemoglobin A1c, IFCC = International 
Federation of Clinical Chemistry, NGSP = National Glycohemoglobin Standardization Program, PCI = 
percutaneous coronary intervention, SD = standard deviation, T1DM = type 1 diabetes mellitus, T2DM = type 
2 diabetes mellitus. Table adopted from the manuscript of Study II and modified. 
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Table 10. Odds ratios with 95% CIs for AKI after CABG in patients with T1DM and T2DM 
 All patients No diabetes a T1DM T2DM 
No. of patients 36 106 30 525 457 5124 
No. of events (AKI) (%) 5199 (14) 4017 (13) 145 (32) 1037 (20) 
   OR (95% CI)  
Risk for AKI (crude analysis)  1.00 3.07 (2.51-3.74) 1.67 (1.55-1.81) 
Risk for AKI (multivariable 
adjusted b )  1.00 4.89 (3.82-6.25) 1.27 (1.16-1.40) 
a Reference category 
b The final multivariable model included all variables presented in the table of characteristics (Table 9) except 
EuroSCORE, hemoglobin A1c concentration, and duration of diabetes. 
Table adopted from the manuscript of Study II and modified. 
AKI = Acute kidney injury, CABG = Coronary artery bypass grafting, CI = confidence interval, OR = Odds 
ratio, T1DM = Type 1 diabetes mellitus, T2DM = Type 2 diabetes mellitus. 
 
 
 
 
 
 
 
Figure 5. 
The illustration to the left shows three separate definitions of AKI:  
AKI 1, increase in SCr concentration of ≥26 µmol/L or ≥50%; reference group, increase of 
<26 µmol/L or <50%. 
AKI 2, increase in SCr concentration of ≥100%; reference group, increase of <100%. 
AKI 3, increase in SCr concentration of ≥200% µmol/L; reference group, increase of 
<200%. 
The illustration to the right shows odds ratios with 95% confidence intervals for the risk of 
AKI from separate analyses according to the three definitions of AKI. The multivariable 
adjusted analysis included all variables in Table 9 except EuroSCORE, hemoglobin A1c 
concentration, and duration of diabetes. 
All analyses showed significant results except the multivariable adjusted analysis of T2DM 
and the risk of the AKI 3 with an OR of 1.27 (95% CI, 0.97–1.68). 
The figure was adopted from the manuscript of Study IV and modified. 
AKI = Acute kidney injury, SCr = Serum creatinine, T1DM = Type 1 diabetes mellitus, 
T2DM = Type 2 diabetes mellitus. 
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Table 11. Odds ratios for risk for AKI according to T2DM treatment regimens. 
 T2DM 
 
Reference 
group a 
Diet treatment 
only 
Oral 
hypoglycemic 
medication 
Insulin treatment with 
or without oral 
hypoglycemic 
medication 
No. of patients 30 525 999 2321 1804 
No. of events (%) 4017 (13) 182 (18) 413 (18) 442 (25) 
 Odds Ratio (95% Confidence Interval) 
Risk for AKI (crude analysis) 1.00 1.47 (1.25–1.73) 1.43 (1.28–1.60) 2.14 (1.91–2.40) 
Risk for AKI (multivariable 
adjusted b ) 1.00 1.13 (0.93–1.38) 1.23 (1.08–1.41) 1.82 (1.61–2.06) 
a No diabetes diagnosis. b The multivariable adjusted model included all variables in Table 9, except diabetes 
duration, hemoglobin A1c, and EuroSCORE. Table adopted and modified from the manuscript of study II. 
AKI = Acute kidney injury, T2DM = Type 2 diabetes mellitus. 
 
STUDY III – AKI AND RISK OF HEART FAILURE 
Results  
In total, 24,018 patients were included in the study, and the overall incidence of AKI was 
12%. Patients with AKI were older, had a lower estimated GFR, and were more likely to 
have diabetes mellitus, hypertension, peripheral vascular disease, a severely reduced LVEF, 
and prior myocardial infarction or stroke. The patients’ characteristics are presented in Table 
12. During a mean follow-up of 4.1 ± 2.4 years, 5.5% of the patients were hospitalized for 
heart failure. A total of 12.0% of patients with AKI were hospitalized for heart failure 
compared with 4.7% of patients without AKI. The results of the primary analysis are 
presented in Table 13, and the Kaplan–Meier curve on the cumulative incidence of heart 
failure is presented in Figure 6. There was a significant association between AKI and risk of 
heart failure, and the hazard ratio increased with each stage of AKI even after multivariable 
adjustment (Table 13). 
The median length of hospital stay was 6 days for patients without AKI and 7, 7, and 9 days 
for patients with AKI stages 1, 2, and 3, respectively. The complete case analysis showed 
results similar to those of the primary analysis with hazard ratios of 1.57 (CI, 1.27–1.95), 1.72 
(CI, 1.35–2.18), and 1.83 (CI, 1.33–2.51) for AKI stages 1, 2, and 3, respectively. The results 
from the analysis using a definition of AKI according to the AKIN criteria were similar to the 
primary definition. These results are presented in the supplementary table in the manuscript 
of Study III. The mortality rate during follow-up was 14% for no AKI, 21% for stage 1 AKI, 
28% for AKI stage 2, and 38% for AKI stage 3. The multivariable adjusted hazard ratios for 
the secondary outcome of heart failure or death for AKI stages 1, 2, and 3 compared with 
patients with no AKI was 1.31 (CI, 1.17–1.46), 1.60 (CI, 1.42–1.80), and 2.13 (CI, 1.82–
2.49), respectively. 
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Discussion 
The main finding in Study III is that AKI after CABG is associated with an increased long-
term risk of developing heart failure. This finding was consistent even after adjustment for 
several risk factors for both AKI and heart failure. 
During follow-up, 5.5% of the patients developed heart failure. It is possible that we 
underestimated the true incidence of heart failure because some patients who developed heart 
failure might not have been hospitalized during follow-up. These patients may have been 
cared for in an out-patient setting. Also, sicker patients tend to develop AKI to a greater 
extent than healthier. It is possible that sicker patients are more sensitive to mild symptoms of 
heart failure and thereby tend to seek hospital care to a greater extent during follow-up. This 
can lead to an overestimation on the association between AKI and heart failure. On the other 
hand, it is not sure that they will be diagnosed with heart failure and that it will be the primary 
discharge diagnosis. There might also be fatal events of heart failure that was not included in 
the study. This could bias the results if either the AKI group or the no AKI group tend to 
develop fatal heart failure to a greater extent. However, the incidence of fatal heart failure 
was likely rather low and would therefore not alter the results significantly. 
Patients who underwent surgery close to the end of follow-up, might have contributed with 
person-years but did not have time to develop heart failure symptoms. The induction time of 
heart failure after AKI might have caused an underestimation of the association between AKI 
and long-term risk of heart failure in this study. The curves in Figure 6 show that the 
derivative/slope of the curves are higher in each stage of AKI during the first year. This 
difference in the incidence rates during the first year indicate a risk of underestimation of the 
association if the time from surgery to the end of follow-up was shorter than 1 year. 
A strength of the study is the large study base and the long follow-up. The study was national 
and represented the Swedish population of CABG patients in the 21st century. A limitation is 
that we had no information on medications before surgery or during follow-up. For example, 
physicians who identified AKI after CABG might have stopped the prescription of 
angiotensin-converting enzyme inhibitors, which also have preventive effects on heart failure. 
These medications may have confounded the association. 
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Table 12. Baseline characteristics of the study population in Study III 
   AKI stagea 
 All patients No AKI 1 2 3 
Number of patients 24 018 21 239 1428 927 424 
Percent of study population 100 88 6.0 3.9 1.8 
Age (SD), y 67 (9) 66 (9) 70 (9) 71 (9) 70 (9) 
Female sex 21% 21% 20% 21% 20% 
Estimated GFR (SD), ml/min/1.73 m2 77 (21) 78 (20) 73 (23) 68 (26) 58 (25) 
Preoperative SCr (SD), µmol/L 92 (26) 90 (22) 98 (33) 107 (40) 131 (64) 
Diabetes mellitus 23% 22% 27% 33% 37% 
Hypertension 57% 56% 65% 72% 77% 
Hyperlipidemia 61% 60% 61% 62% 70% 
Peripheral vascular disease 8.9% 8.3% 13% 13% 18% 
Current smoking 18% 18% 15% 18% 15% 
Prior MI 36% 35% 40% 43% 52% 
Prior stroke 4.8% 4.4% 6.9% 7.0% 12% 
Left ventricular ejection fraction      
Ejection fraction >50% 73% 74% 68% 64% 61% 
Ejection fraction 30% to 50% 24% 23% 28% 32% 33% 
Ejection fraction <30% 2.7% 2.5% 3.7% 4.0% 6.2% 
Internal thoracic artery use 94% 94% 95% 94% 93% 
CABG without cardiopulmonary bypass 5.9% 5.6% 6.7% 7.9% 8.7% 
Year of surgery      
2000-2004 56% 56% 56% 59% 55% 
2005-2008 44% 44% 44% 41% 45% 
aAKI was defined according to an absolute increase in the SCr concentration: stage 1, 26 to 44 µmol/L; stage 
2, 44 to 88 µmol/L; stage 3, >88 µmol/L.  
AKI = acute kidney injury, CABG = coronary artery bypass grafting, eGFR = estimated glomerular filtration 
rate, MI = myocardial infarction, SCr = serum creatinine, SD = standard deviation. 
Table adopted from the manuscript of Study III and modified. 
 
 
Table 13. Hazard ratios of first hospitalization for Heart Failure with 95% CIs in relation to AKIa 
  AKI a 
 No kidney injuryb Stage 1 Stage 2 Stage 3 
No. of patients % 21 239 1428 927 424 
Per cent of population 88.4 5.6 3.9 1.8 
No. of events, % 997 (4.7) 141 (9.9) 122 (13.2) 65 (15.3) 
 Hazard ratio (95% CI) 
Crude 1.00 2.22 (1.86-2.65) 3.10 (2.57-3.74) 3.95 (3.08-5.08) 
Adjustment for age and sex 1.00 1.87 (1.57-2.23) 2.48 (2.05-2.99) 3.29 (2.56-4.23) 
Multivariable adjustmentc 1.00 1.60 (1.34-1.92) 1.87 (1.54-2.27) 1.98 (1.53-2.57) 
a AKI classified according to absolute increase in serum creatinine concentration: stage 1, 26 to 44 µmol/L; 
stage 2, 44 to 88 µmol/L; stage 3, >88 µmol/L.  
b Reference category 
c Multivariable adjustment was made for age, sex, diabetes mellitus, left ventricular ejection fraction, 
estimated glomerular filtration rate, and pre- and postoperative myocardial infarction.  
AKI = Acute kidney injury, CI = confidence interval. 
Table adopted from the manuscript of Study III and modified. 
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STUDY IV – MINIMAL CHANGES IN SERUM CREATININE 
Results 
The study included 25,665 patients. Among these, 40% developed AKI group 1, 6.4% 
developed AKI group 2, and 6.4% developed AKI group 3. Patients who developed AKI 
were older, and had a higher prevalence of a reduced estimated GFR, and had a higher 
prevalence of previous myocardial infarction, stroke, and heart failure (Table 14). The 
relative risks for long-term mortality, 30-day mortality, and the composite outcome of long-
term mortality, myocardial infarction, heart failure, and stroke are presented in Table 15. 
Long-term mortality 
During a mean follow-up of 6.0 years, 17% of the patients died. The long-term mortality was 
14% in patients without AKI. The long-term mortality in patients with group 1, 2, and 3 AKI 
was 16%, 25%, and 40%, respectively. The cumulative incidence of long-term mortality is 
illustrated by the Kaplan–Meier curve in Figure 7. 
Figure 6.  
Kaplan-Meier curve showing the cumulative incidence for a first 
hospitalization of heart failure according to stage of acute kidney injury. 
The inset presents the same data zoomed in on the first three years. 
Figure adopted and modified from the manuscript of study III. 
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30-day mortality 
The 30-day mortality was 1.0% among all patients. The 30-day mortality among patients with 
group 1, 2, and 3 AKI was 0.5%, 2.8%, and 8.4%, respectively. The 30-day morality 
according to changes in the SCr concentrations is illustrated in Figure 8. 
Combined outcome of long-term mortality, heart failure, myocardial infarction, and 
stroke 
During a mean follow-up of 3.7 years, 28% of patients died or were hospitalized for 
myocardial infarction, heart failure, or stroke. The absolute risk of reaching the composite 
outcome during follow-up was 24% among patient without AKI, and in group 1, 2, and 3 
AKI it was 26%, 39%, and 54%, respectively. 
Discussion 
The main finding in Study IV was that a minimal increase in the SCr concentration of 0 to 26 
µmol/L after CABG was associated with an increased risk of long-term mortality and 
cardiovascular outcomes, and a small but not minimal increase of 26 to 44 µmol/L was 
associated with 30-day mortality. 
Figure 8 shows that the 30-day mortality curve has an exponential shape and starts to 
accelerate at approximately 18 µmol/L. However, we found no significant association 
between a minimal increase in the SCr concentration of 0 to 26 µmol/L and 30-day mortality. 
A significant association was on the other hand found in the analyses on long-term mortality, 
and the combined outcome. AKI group 2, which corresponded to the absolute increase in the 
SCr criteria for AKIN and KDIGO stage 1, was associated with increased risk of all 
outcomes in the study. The author therefore argues that the results validate the absolute SCr 
criteria for AKIN and KDIGO and that a lower threshold is not valuable due to conflicting 
results. The conflicting results suggest that there might be something happening to the 
kidneys that is not always showing clinical changes in GFR. Upcoming AKI biomarkers 
might in the future work as a complement in the group of patients with minimal increases in 
SCr. 
The mean follow-up time was 6.0 years in the primary analysis of long-term mortality, and 
3.7 years in the secondary analysis in which hospitalization for heart failure, myocardial 
infarction, and stroke were added to the death as outcome. Notably, 28% of patients 
developed the combined outcome before end of follow-up. The follow-up time from the 
analysis might seem short; however, calculation of the time from surgery to the date on which 
no more data on outcomes were available (February 2011 for survival status and December 
2008 for heart failure, myocardial infarction, and stroke) shows that the patients had a mean 
time of 4.5 years to develop myocardial infarction, heart failure, and stroke and 6.6 years for 
long-term mortality. 
A weakness of the study is that we did not perform separate analyses on the cardiovascular 
outcomes. Different associations may exist between various diseases and AKI. Another 
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weakness is that we had no information on the amount of fluids given during or after surgery 
and were therefore unable to estimate the degree of hemodilution after surgery. 
 
Table 14. Baseline characteristics of the study population in Study IV.  
Variable All patients No AKI AKI groups
a 
1 2 3 
Number of patients 25 665 12 066 10 322 1631 1646 
Percent of study population 100 47 40 6,4 6,4 
Women 21% 23% 20% 20% 21% 
eGFR (ml/min/1.73 m2), mean (SD) 77 (21) 75 (19) 82 (21) 72 (23) 63 (26) 
Preoperative SCr concentration (µmol/L), 
mean (SD) 92 (27) 93 (23) 87 (22) 99 (33) 117 (50) 
Diabetes mellitus 24% 21% 23% 28% 36% 
Hypertension 58% 54% 58% 64% 72% 
Hyperlipidemia 61% 60% 60% 60% 65% 
Peripheral vascular disease 9.4% 8.4% 8.9% 13% 16% 
Current smokers 18% 19% 17% 14% 17% 
Chronic obstructive pulmonary disease 6.2% 6.4% 5.6% 6.9% 8.4% 
Previous MI 36% 35% 36% 40% 48% 
Previous stroke 5.0% 4.3% 4.8% 7.6% 9.1% 
Previous congestive heart failure 4.1% 3.4% 3.6% 6.3% 10% 
Left ventricular ejection fraction      
Ejection fraction >50% 71% 73% 72% 65% 58% 
Ejection fraction 30% to 50% 25% 24% 24% 29% 35% 
Ejection fraction <30% 3.8% 3.3% 3.5% 5.3% 7.6% 
Internal thoracic artery use 94% 94% 94% 94% 94% 
CABG without cardiopulmonary bypass 5.8% 5.5% 5.8% 6.7% 7.5% 
Waiting time <7 days 23% 22% 23% 25% 27% 
aAKI groups were defined according to an absolute increase in SCr conentration: no AKI, <0 µmol/L; group 
1, 0 to 26 µmol/L; group 2, 26 to 44 µmol/L; group 3 >44 µmol/L.  
AKI = acute kidney injury, CABG = coronary artery bypass grafting, eGFR = estimated glomerular filtration 
rate, MI = myocardial infarction, SD = standard deviation, SCr = Serum Creatinine. 
Table adopted an modified from the manuscript of study IV. 
 
Table 15. Relative risks in relation to AKI group 1 to 3a for all-cause mortality within 30 days, long-term 
mortality, and the combined outcome of long-term death, myocardial infarction, heart failure, and stroke  
Outcome No kidney injury AKI groups 
1 2 3 
Number of patients 25 665 10 322 1631 1646 
     
30-day all-cause mortality Odds ratio (95% CI) 
Crude  1.34 (0.91-1.99) 4.63 (2.91-7.38) 23.4 (16.7-32.7) 
Multivariable adjustmentb  1.37 (0.84-2.21) 3.64 (2.07-6.38) 15.4 (9.98-23.9) 
Long-term all-cause mortality Hazard ratio (95% CI) 
Crude  1.16 (1.08-1.24) 1.93 (1.73-2.15) 3.75 (3.43-4.10) 
Multivariable adjustmentb  1.07 (1.00-1.15) 1.33 (1.19-1.48) 2.11 (1.92-2.32) 
Combined end-pointc Hazard ratio (95% CI) 
Crude  1.15 (1.10-1.22) 1.86 (1.71-2.03) 3.12 (2.90-3.37) 
Multivariable adjustmentb  1.09 (1.03-1.15) 1.39 (1.27-1.52) 1.99 (1.84-2.16) 
aAcute kidney injury groups were defined according to the increase in the serum creatinine concentration 
from the preoperative to postoperative periods: group 1, 0 to 26 µmol/L; group 2, 26 to 44 µmol/L; group 3, 
>44 µmol/L; and no kidney injury, ≤0 µmol/L (reference group). 
bMultivariable adjustments were made for age, chronic obstructive pulmonary disease, heart failure, diabetes 
mellitus, estimated glomerular filtration rate, left ventricular ejection fraction, myocardial infarction, 
peripheral vascular disease, sex, and stroke (all prior to surgery). 
cThe combined outcome includes heart failure, stroke, myocardial infarction, and long-term death. 
Table adopted from the manuscript of Study IV and modified. 
AKI = Acute kidney injury, CI = confidence interval. 
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Figure 8. 
Illustration of the 30-mortality 
and number of patients 
according to change in post- 
compared to pre-operative serum 
creatinine concentrations.  
Figure adopted and modified 
from the manuscript of study IV. 
Figure 7. 
Kaplan–Meier 
curve on the 
cumulative 
incidence of long-
term death 
according to acute 
kidney injury 
group. AKI = acute 
kidney injury. 
Adopted from the 
manuscript of 
Study IV and 
modified. 
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INTERPRETATION AND OVERALL DISCUSSION 
 
SUMMARY OF FINDINGS 
In this thesis of observational cohort studies, we identified risk factors for and outcomes of 
AKI in patients undergoing cardiac surgery. We also investigated the prognostic value of 
minimal increases in postoperative SCr concentrations. Treatment with teicoplanin and a 
comorbidity of diabetes were associated with the development of AKI. AKI after surgery was 
associated with increased long- and short-term mortality, heart failure and a combined 
outcome of long-term mortality, heart failure, myocardial infarction, or stroke. Minimal 
increases in SCr of 0 to 26 micromol/L was associated with an increased long-term mortality 
and cardiovascular outcomes, but not 30-day mortality. Due to the conflicting results of 
prognosis in relation to minimal increases in SCr, it is not motivated to include minimal 
increases in SCr in the AKI stage 1 criteria according to KDIGO or AKIN. 
 
METHODOLOGICAL CONSIDERATIONS  
Internal validity 
A main goal in performing Studies I to IV was to obtain the most accurate results possible 
and coming close to the true associations between the exposures and outcomes. However, 
epidemiologic studies are associated with several pitfalls, many of which have been named 
and categorized for a better understanding and prevention. As discussed below, the accuracy 
of study results can decrease due to systematic error and random error. 
Systematic error (bias) 
Systematic error, also called bias, is a built-in error that makes all study results incorrect to a 
certain extent. A systematic error is not dependent on the size of the study. Therefore, unlike 
random error, systematic error cannot be mended by increasing the sample size which is the 
case with random error. Systematic error is comparable to a good sniper using an incorrectly 
calibrated sniper scope that causes all shots to be close to one another but located alongside 
the bullseye. Systematic error is dependent on the study design. In general, systematic error in 
epidemiologic studies can be divided into three broad categories: selection bias, information 
bias, and confounding (148). Systematic error may not be fixed afterward, but the extent of it 
may be estimated. Thus, the best way to handle systematic error is to avoid it. 
Selection bias is a systematic error related to factors that influence participation in either the 
exposed group or the unexposed group. For example, patients with a hereditary disposition 
for cancer might be more interested in participating in a new cancer screening program. 
Comparison of the screened patients (exposed group) with unscreened patients might seem to 
indicate that the screening program identifies more patients with cancer, but the true cause of 
the higher number of identified is that this group had a higher baseline risk of cancer (148). 
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In Studies II to IV, we excluded patients with missing preoperative or postoperative SCr 
concentrations. Exclusion of patients with missing information can introduce selection bias if 
the excluded population differs from patients with complete information. In this case, the 
selection bias will affect the results if there is a different association between the exposure 
and the outcome in the excluded group as compared to the group included in the study. No 
such systematic error was identified in our data. In fact, our research group investigated the 
patients with missing values in the cohorts of Studies III and IV. Patients with missing data 
had the same baseline characteristics and risk of long-term mortality as did patients with 
complete information on the SCr concentration (unpublished data). 
Information bias arises when the gathered data on the study subjects is incorrect (148). 
There are many categories of information bias, and one example is misclassification. 
Misclassification of dichotomous variables arises when the study subjects are assigned to the 
wrong category. Using Study III as an example, some patients might have been diagnosed 
with heart failure but did not fulfill all criteria for heart failure. If the tendency to 
overdiagnose the outcome of heart failure is higher in the exposed group (AKI group), the 
risk of developing heart failure would be overestimated and the misclassification would be a 
differential misclassification of the outcome. If the tendency to overdiagnose heart failure is 
equal in the exposed and unexposed groups, the risk would not be overestimated and the 
misclassification would be nondifferential. A nondifferential misclassification does not result 
in overestimation or underestimation of the effect, but because more patients would be 
classified as having heart failure unrelated to whether they were exposed or not, the 
association would seem weaker. The effect size would thereby be diluted and the relative risk 
would approach 1. All epidemiological studies are affected by nondifferential 
misclassification to some extent. 
Our studies were dependent on valid diagnoses to obtain accurate results. Classification of 
AKI was based on values from laboratory analyses, and the laboratories were blinded to the 
patients’ status. However, the frequency of obtaining blood samples might have been higher 
in sicker patients or patients with postoperative complications. Therefore, we might have 
identified more cases of AKI in the sicker group because of increased sampling. This 
misclassification of the exposure can lead to overestimation of the association between AKI 
and morbidity and mortality. On the other hand, we used the highest postoperative SCr 
concentration during the entire postoperative period. Thus, the diagnosis of AKI in the 
healthier population was not likely to have been missed to a great extent.  
A confounder is a factor that is associated with the exposure and outcome but is not part of 
the causal pathway (Figure 9) (148). For example, an association may be present between 
cocaine use and myocardial infarction. However, age could be a confounder in this case 
because the risk of myocardial infarction increases with higher age, and younger individuals 
tend to use cocaine to a greater extent. Age is thereby related to both the studied exposure and 
outcome. If we adjust for age, we can estimate the effect of cocaine use regardless of age. If 
cocaine use leads to tachycardia with subsequent cardiac ischemia and myocardial infarction, 
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tachycardia would be an intermediate factor in a causal pathway. When investigating the 
association between cocaine use and the risk of myocardial infarction, it would be incorrect to 
adjust for tachycardia because this is the mechanism which mediates the causal relationship 
between cocaine and myocardial infarction.  
 
 
 
 
In Studies I to IV, we handled confounding using multivariable statistical models and 
stratified analyses. These are statistical methods to handle confounding. There are also 
methods during data collection to decrease confounding such as randomization, restriction, 
and matching (148). These methods were not used because we used already-sampled data. 
The analyses in Studies I to IV were adjusted for the most important risk factors for 
perioperative AKI described in the literature (30). However, we cannot rule out the presence 
of residual confounding. In Studies II to IV, we did not adjust for perioperative risk factors 
for AKI such as the use of cardiopulmonary bypass or the cross-clamp time because these 
factors can be part of a causal pathway of AKI and cardiovascular outcomes. In Study I, we 
investigated a specific causal pathway, and the perioperative risk factors were thereby eligible 
for inclusion in the multivariable model. Deep hypothermic circulatory arrest was included in 
the final model. 
Random error - Precision 
Random error is variability in the study data that cannot be explained. The random error is 
thereby derived from a lack of knowledge or lack of detail of the data. For example, if a 
rubber ball is thrown onto an irregular surface, the direction in which the ball will bounce is 
difficult to predict and might be interpreted as random. If the ball is thrown 10,000 times and 
the outcome is measured, it would be possible to draw conclusions regarding the most likely 
angle and distance the next time the ball is thrown. The most likely intervals of direction and 
length within which the ball will stay can also be calculated. If the exact angle, force, and 
configuration of the surface can be measured, then the direction in which the ball bounces 
would not be random and the results could be predicted with higher precision. 
Figure 9.  
Illustration showing a 
confounder and an 
intermediate factor and their 
relationships to an exposure 
(cocaine use) and outcome 
(myocardial infarction). 
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The precision of the point estimates in Studies I to IV was indicated by the 95% CIs. 
Simplified, this means that there is a 95% likelihood that the true value is within this interval. 
Notably, calculated precision does not take systematic error into account. When a CI does not 
include the null hypothesis (often a relative risk of 1), the result is considered statistically 
significant. The p value is traditionally used for hypothesis testing. The definition according 
to Fisher, who promoted the widespread use of p values in medical statistics, can be 
summarized as follows: “the probability that the null hypothesis is true according to an 
observation, plus more extreme values” (149). The CI and p value can be calculated from the 
same equation, and presenting both a p value to a CI does not add information. The 95% CI 
and a p value of <0.05 are somewhat arbitrary levels of confidence commonly used in 
medical research (148). 
Of importance, a significant result is neither equal to the effect size nor clinical importance. A 
study of 36,106 patients, as in Study II, will in this case provide plentiful significant results 
when comparing variables. In this study, we found that T1DM and T2DM had a 
multivariable adjusted hazard ratio of 4.89 and 1.27, respectively. The importance of the 
calculated effect size depends on the clinical context, specifically how common the exposure 
is and the severity of the outcome or secondary consequences. The hazard ratio of 1.27 found 
in Study II might seem low, but considering that 14% of the patients who underwent CABG 
had T2DM and that the consequences of perioperative AKI are severe in terms of associated 
complications and health care costs, the author argues that this rather low hazard ratio has an 
important impact on patients undergoing cardiac surgery. 
External validity / Generalizability  
External validity also called generalizability, is the ability to apply the results from a sample 
or cohort to other samples or cohorts, for example, among other hospitals, an entire country, 
other countries, or other ethnic and socioeconomic groups. Study I was a single-center study 
of a general cardiac surgery population. Studies II to IV were nation-wide studies; they 
included patients who underwent nonemergent CABG from all cardiac surgery sites in 
Sweden. In Sweden, there is no policy to send sicker adult patients to a certain center for 
CABG or regular valve surgery. The characteristics of the patients in Study I should therefore 
not differ significantly from those of the patients in Studies II to IV. The patient’s 
characteristics were similar between Study I and Studies II to IV (Tables 7, 9, 12, 14). 
Additionally, the demographics and comorbidities were comparable between patients in 
Studies I to IV and cohorts from European studies, Australia, and the United States (150–
152). The cardiac surgery procedures in Sweden are also largely standardized and 
comparable with those in other countries with similar health care. Therefore, the author 
believes and that our results are generalizable to other countries with similar health care. 
Whether the results of Studies I to IV are generalizable to populations undergoing other types 
of surgical procedures, such as major abdominal surgery or orthopedic surgery, is uncertain. 
The use of perioperative cardiopulmonary bypass is unique to cardiac surgery, and whether 
the AKI-associated outcomes following cardiac surgery are similar to those following other 
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procedures is not answered in our studies. Separate studies in other surgical settings are 
needed to draw general conclusions regarding this issue. In fact, results from other surgical 
settings such as major abdominal and orthopedic surgery have shown that AKI is associated 
with increased mortality and complications (153,154). The results of our studies thereby 
show consistency not only with prior studies in cardiac surgery (155,156), but also with other 
surgical settings (153,154). 
 
INTERPRETATION OF FINDINGS 
The strong association between AKI, CKD, cardiovascular disease, and their risk factors 
makes it difficult to interpret what perioperative AKI really means and causes. In Study II, we 
found that both T1DM and T2DM are risk factors for AKI. Diabetes is also a general risk 
factor for the development of CKD and cardiovascular disease even outside the cardiac 
surgery setting (117–119). In Studies III and IV, we found an association between AKI and 
the risk of developing heart failure as well as between AKI and the composite outcome of 
long-term mortality, heart failure, myocardial infarction, and stroke. One might wonder if 
perioperative AKI is more a sign of cardiovascular disease than an important event on its 
own. Does AKI really cause disease? Is AKI during surgery merely a cardiovascular and 
renal stress test comparable to the cardiologist’s exercise stress test that reveals ischemic 
heart disease? Irrespective of this, AKI remains of interest because it provides information on 
the patient’s prognosis; however, would research on AKI prevention and treatment be 
meaningful? The schematic illustration in Figure 10 shows the associations found by our 
research group and indicates that all pathways could bypass a causal effect of AKI and 
outcomes. These speculations challenge the two assumptions held by many AKI researchers: 
that the frequency of perioperative AKI is modifiable and that a decreased incidence of 
perioperative AKI will improve patients’ outcomes. Based on the pathways illustrated in 
Figure 10, it might be easy to reject the above-mentioned assumptions. Unfortunately, it will 
be difficult to perform a human study that allows for identification of a causal pathway from 
AKI to, for example, cardiac injury (CRS type III or IV). What we can do, however, is to use 
the currently available evidence and step by step reason regarding a possible causal pathway: 
- AKI can be caused by factors that do not primarily injure any organs except the 
kidneys. These causes of AKI are not dependent upon risk factors for either 
cardiovascular disease or AKI, nor are they dependent upon a systemic disease. For 
example, primarily nephrotoxic factors include exposure to different toxins such as 
orellanine from mushroom poisoning, snake bites, or rhabdomyolysis (157–159). It is 
fully reasonable that medications can also be primarily nephrotoxic. In Study I, we 
showed that teicoplanin was associated with AKI. Correct medical treatment can likely 
modify the frequency of perioperative AKI. 
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- AKI can lead to CKD, and there is a dose-dependent relationship between the severity 
of AKI and long-term renal function in various clinical settings including cardiac 
surgery, intoxications, rhabdomyolysis, and sepsis (4,158–161). 
- Studies have shown that renal transplantation can reverse a decreased LVEF and left 
ventricular hypertrophy (162). A recent study also showed that healthy kidney donors 
later developed signs of increased left ventricular mass, an increased mass–volume ratio, 
and increased serum concentrations of troponin T (163). This implies a causal 
relationship between chronic loss of renal function and cardiovascular disease. There are 
also functions unique to the kidney that can cause distant organ effects. A decrease in 
urine production is associated with a risk of fluid overload, electrolyte disturbances, and 
accumulation of metabolites that can stress distant organs such as a failing heart (116).  
 
Considering the above statements, one can argue that AKI is not only a sign of cardiovascular 
disease but that it can also have long-term causative effects. The evidence regarding the acute 
effects of AKI is weaker. In Study IV, we found that the development of AKI after CABG 
was associated with 30-day mortality. Is this due to a primary cardiac injury leading to 
decreased cardiac output or to other factors external to the kidneys that run parallel with 
AKI? Or does AKI have an impact on 30-day mortality on its own? As mentioned in the 
background section, animal studies have shown that AKI causes acute distant organ effects 
Figure 10.  
Illustration of selected associations found in epidemiological studies of AKI suggesting 
several possible causal connections and confounding factors. Green boxes represent renal 
outcomes, red boxes represent cardiovascular outcomes, and blue boxes represent risk 
factors for either renal or cardiovascular outcomes. The text above the arrows are 
examples of studies that found the stated association.  
AKI = acute kidney injury, CKD = chronic kidney disease. 
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not only by fluid overload and electrolyte disturbances (122). These studies found that the 
inflammatory mediators involved in AKI are the same as those involved in toxic 
cardiomyopathy. Additionally, even if the primary cause of AKI is reduced cardiac function, 
it is possible that AKI will further worsen the cardiac function by inflammation, fluid 
overload, and activation of the renin-angiotensin-aldosterone system (60). 
In summary, the author argues that there is a strong association between perioperative AKI 
and a worse prognosis. This is likely due to a combination of both AKI as a sign of 
cardiovascular disease and AKI as a cause of cardiovascular disease with CKD or decreased 
renal functional reserve as intermediate steps. There may also be short-term effects of AKI 
that influence the outcome. The abovementioned assumptions of AKI research are plausible, 
and interventional AKI studies are meaningful. Further exploration on the casual pathway of 
AKI should be performed by interventional studies in which a decreased incidence of AKI is 
followed up with respect to associated complications. 
 
FUTURE RESEARCH 
Improved interventional studies 
The impact of AKI on patients’ prognosis is receiving increasingly more attention in 
research. AKI has been found to be associated with a worse prognosis in various settings such 
as intensive care, major abdominal surgery, and orthopedic surgery (153,154,164). In Studies 
I to IV, we further investigated AKI in the cardiac surgery setting. A natural next step would 
be studies on the prevention and treatment of AKI. Two very common clinical settings in 
which prevention of AKI could be effective are cardiac surgery and administration of 
iodinated contrast media (165). However, no studies have identified effective preventive 
interventions in these settings. In many cases, studies have shown severe methodological 
limitations (165). A challenge inherent to the study of perioperative AKI is its multifactorial 
causes. It is unlikely that one single intervention will lead to a great decrease in the incidence 
of AKI. Thus, interventional studies must be large to ensure sufficient statistical power. Many 
of the interventional AKI studies with absent or inconclusive statistical significance included 
around 50 to 500 patients (166–168). These studies were likely deemed to fail from the 
beginning considering the following power calculation example: 
In Study II, the baseline incidence of AKI was around 14%. If the effect size of a potential 
intervention is assumed to reduce the risk of AKI by 25%, the event rate in the treatment 
group would be 10.5%. A power calculation using α = 0.05 and 1 − β = 0.8 (80% power) 
would result in a required sample size of 2866 patients. If the intervention instead would be 
assumed to reduce the risk of AKI by 50% (huge effect), the required sample size would be 
656 patients.  
Large interventional studies are expensive. The sample size can be decreased using risk 
stratification scores that increase the baseline incidence of AKI in the cohort. If we could use 
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a prediction score to identify a cohort in which the baseline risk of AKI is 50% and we 
assume an effect size of a 50% reduction in AKI, the required sample size would be 524 
patients. Hence, good AKI prediction models are needed. New biomarkers might play an 
important role in the future for improved prediction models. Also, we are likely often too late 
and have missed the opportunity for AKI treatment. Biomarkers may improve the timing of 
the intervention and thereby improving the effect size.  
To ensure a progress in AKI prevention and treatment studies, the author argues that there are 
needed studies with adequate statistical power, improved prediction scores, and further 
exploration of AKI biomarkers. 
Follow up studies 
Several ideas for follow-up studies emerged in the aftermath of performing Studies I to IV. In 
Study I, treatment with teicoplanin was associated with the development of AKI after 
surgery. It would be interesting to perform a long-term follow-up study to determine whether 
teicoplanin treatment is associated with the development of CKD, cardiovascular outcomes, 
death, and postoperative infections. This will help to evaluate the costs and benefits of 
teicoplanin treatment. Such a study could also provide insight regarding a causal relationship 
between AKI and outcomes of cardiac surgery. However, a challenge in this follow-up study 
would be adequate statistical power because the incidence of AKI between the teicoplanin 
and reference group differed by only 3 percentage units, and the cumulative incidence of 
heart failure, myocardial infarction, stroke, and death was around 28%. Another challenge is 
the fact that teicoplanin treatment was not randomized. 
In Study III, we found an association between AKI and a long-term risk of heart failure. It 
would be interesting to determine how much of this long-term risk of developing heart failure 
is explained by an intermediate step of CKD. Such a study could use SCr from laboratory 
registers for identification of CKD. 
Study settings for cardio-renal syndrome type III investigations 
The causal relationship between AKI and outcomes is difficult to study in humans because 
we do not want to induce AKI in a randomized group of patients. For further conclusions on 
the acute effects of AKI (CRS type III), we must identify clinical settings that could simulate 
an experimental setting. In this thesis, we used cardiac surgery as a model for AKI. 
Interesting settings for investigating the acute effects of AKI are renal transplantation and 
nephrotoxin exposures: 
Transplantation surgery 
CKD is associated with cardiac abnormalities such as ventricular hypertrophy, systolic and 
diastolic dysfunction, and left ventricular dilatation (162). A recent study revealed improved 
cardiac function and structure in a long-term follow-up after kidney transplantation (169). 
This group of patients would be interesting to study further. When inserting a new (likely 
ischemic) kidney in patients with renal failure, will the same inflammatory markers be 
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released as in animal models of ischemic kidney disease? Will this have an effect on graft 
prognosis or future cardiovascular disease? Will sensitive measurements of cardiac function 
reveal any acute changes? 
Kidney donors exhibit a sudden decline in GFR. Will there be acute hemodynamic alterations 
and changes in the renal angiotensin aldosterone system? Will there be acute changes in 
cardiac function? 
Acute kidney injury from toxin exposure 
Exposure to various nephrotoxins, such as orellanine intoxication, may lead to severe AKI 
and subsequent CKD. Some patients have no cardiovascular risk factors before exposure. Do 
these intoxications have short-term effects on cardiac function and structure or on blood 
inflammatory markers? What is the long-term risk of cardiovascular disease? 
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CONCLUSIONS 
 
The overall aim of this thesis was to further investigate the risk factors for and outcomes of 
AKI in patients undergoing cardiac surgery. The main findings were as follows. 
 
Study I Antibiotic prophylaxis with teicoplanin in patients undergoing cardiac surgery 
was associated with an increased risk of developing AKI. 
 
Study II T1DM and T2DM were associated with an increased risk of AKI in patients 
undergoing CABG irrespective of their preoperative renal function. The risk of 
developing AKI was higher in patients with T1DM than in patients with 
T2DM. 
 
Study III The development of AKI after CABG was associated with an increased long-
term risk of developing heart failure 
 
Study IV A minimal increase in the SCr concentration of 0 to 26 µmol/L was associated 
with increased long-term mortality and an increased risk of the combined 
outcome of long-term mortality, heart failure, myocardial infarction, and stroke. 
A minimal increase in the SCr concentration was not associated with 30-day 
mortality, but those having a minor increase in SCr of 26 to 44 µmol/L had a 
significantly increased 30-day mortality. 
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